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ABSTRACT
Current methods of treating critical size bone defects (CSDs) include autografts
and allografts, however both present major limitations including donor-site morbidity,
risk of disease transmission, and immune-rejection. Tissue engineering provides a
promising alternative to circumvent these shortcomings through the use of stem cells,
three dimensional (3D) scaffolds, and growth factors. Cells receive signals from their
microenvironment that determine cell phenotype, and a combination of physical cues and
chemical factors is thought to have the most profound influence on stem cell behavior. A
major focus of tissue engineering strategies is scaffold design to recapitulate in vivo
microenvironmental architecture to direct stem cell lineage commitment. In combination
with relevant microenvironment design, the success of bone tissue engineering strategies
critically depends on the rapid formation of a mature vascular network in the scaffolds
after implantation. However, conventional approaches fail to consider the role of the host
response in regulating tissue ingrowth and extent of vascularization. The work presented
here focuses on i) designing an osteomimetic 3D substrate to guide human embryonic
stem cell (hESC) differentiation towards bone lineage, and ii) investigating the ability of
the polyphenol resveratrol to harness the potential of the inflammatory response to
enhance angiogenesis and osseointegration in 3D scaffolds for bone repair.
The osteomimetic scaffold with native bone extracellular matrix (ECM)
components successfully directed the osteogenic differentiation of hESCs. A
microsphere-sintering technique was used to fabricate poly(lactic-co-glycolic acid)
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(PLGA) scaffolds with optimum mechanical properties, and human osteoblasts
(hOBs) were seeded on these scaffolds to deposit bone ECM. This was followed by a
decellularization step leaving the mineralized matrix intact. hESCs were seeded on the
osteomimetic substrates in the presence of osteogenic growth medium, and osteogenicity
was determined according to calcium content, osteocalcin expression, and bone marker
gene regulation. The results from this study demonstrate the potential of PLGA scaffolds
with native bone ECM components to direct osteogenic differentiation of hESCs and
induce bone formation.
Engineered resveratrol nanoparticle-incorporated PLGA scaffolds enabled the
concurrent (i) mediation of inflammatory (M1) to wound healing (M2) macrophage
differentiation, (ii) natural release of angiogenic factors by M2 macrophages and (iii)
enhanced osteogenic differentiation of human mesenchymal stem cells (hMSCs). To this
end, we mapped the time-dependent response of macrophage gene expression as well as
hMSC osteogenic differentiation to varying doses of resveratrol. Our results delineate the
potential to synergistically control angiogenic factor secretion and downstream
osteogenic signaling pathways by “dialing” the appropriate degree of resveratrol release
from nanoparticle-incorporated PLGA scaffolds.
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CHAPTER 1: BONE TISSUE ENGINEERING

1.1 Tissue Engineering
In recent years, tissue engineering has emerged as a potential method for treating
numerous diseases and regenerating damaged cells. By applying engineering approaches
to knowledge of biological systems, a tissue engineered substitute can be generated to
restore, replace, or maintain partial if not entire organ function [1]. The key to tissue
engineering strategies is coordinating cell behavior with specific growth factors and
biomaterials in order to regenerate functional tissues, however this is difficult to
experimentally control in vitro.
Like many tissues in the body, bone has a natural ability to repair minor injuries
resulting from disease or small fractures. Despite this, it is estimated that over 800,000
bone graft procedures are completed yearly in the United States to facilitate repair from
large-scale trauma [2-4]. Current treatment methods for critical-sized defects (CSDs)
include (i) autografts, where the patient’s own bone tissue is removed from one area and
placed in the site of deficiency, (ii) allografts, where bone from a cadaver is used to
replace the damaged tissue, (iii) and synthetic grafts, where manufactured materials are
implanted and used to treat the CSD [5-7]. Autografts are considered the gold standard in
clinical applications because of their osteoconductivity, osteoinductivity, and
osteogenecity, however a secondary surgery is required for implementation. There is also
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a risk of disease transfer, rejection by the host, and large bone defects cannot be treated
by autografts [8-13]. Long-term storage of bone tissue for allografts causes bone
architecture to dramatically weaken and most of the osteoprogenitor cells are no longer
viable. Synthetic grafts cannot fully incorporate with the host tissue and are susceptible to
fatigue, fracture, and wear [14]. Therefore, there is a need for better treatment options for
patients with CSDs, and tissue engineering offers bone graft alternatives.

1.2 Bone Physiology and Microenvironment

Bone macrostructure generally has two layers, which includes the outer dense
compact bone and the inner spongy trabecular bone. The compact, or cortical bone,
provides strength and support to the structure. The trabecular bone is porous with cells
interwoven between calcified lattices. Simply described, bone architecture can be broken
down into this sequential arrangement: (i) the macrostructure which is made up of
cortical and cancellous bone, (ii) the microstructure which is composed of osteons,
haversian systems, and trabeculae, (iii) the submicrostructure which is comprised of the
lamellae, (iv) the nanostructure which is predominately composed of collagen I fibers,
and (v) the sub-nanostructure made up of mineralized matrix, smaller collagen subunits,
and other organic proteins [15].
The extracellular matrix (ECM) is a dynamic arrangement of molecules such as
collagen, con-collagenous glycoproteins, hyaluronan, and proteoglycan that are produced
by cells, and in turn, regulate cell phenotype [16]. Native bone ECM is mainly composed
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of type I collagen, upon which carbonated apatite is laid down to create a crystalline
anisotropic fibril [17]. Serum albumin and α2-HS-glycoprotein are noncollagenous
proteins that bind to hydroxyapatite due to their acidic properties [18]. Other
noncollagenous proteins found in bone ECM include osteocalcin, alkaline phosphatase,
osteonectin, osteopontin, and bone sialoprotein [18]. Cells residing in bone ECM secrete
growth factors, matrix-degrading enzymes, and inflammatory mediators [16].
Bone is a highly vascularized tissue. The nutrient or diaphyseal artery, periosteal
arteries, metaphyseal arteries, and epiphyseal arteries are the four arterial inputs that
supply nutrients in adult bones. The nutrient artery is responsible for the bulk of the total
blood supply with over 50% of the blood flow due to its arterial output [19, 20].
Periosteal arteries are responsible for the membrane covering the outside of bones called
the periosteum. The periosteum is a significant source of stem cells and has been utilized
in previous regenerative studies [21, 22]. The diaphyseal nutrient artery enters the shaft
through one or two nutrient foramina leading into the nutrient canals. These arteries then
enter the medullary cavity where they divide into ascending and descending branches to
supply the cortical and marrow microcirculations. The cortical branches of the arteries
passing through the endosteal canals feed the capillaries in the Haversian and
Volkmann’s canals and generally conform to the canal shape [23]. For bone marrow
circulation, capillaries drain into vascular channels surrounded by a layer of fenestrated
endothelium [24, 25]. The central venous sinus is responsible for the draining of the
veins and runs along the paths of the nutrient arteries and leaves the bone through veins
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[20, 23]. Blood flow in the bone generally occurs at 5-20 ml/min per 100 grams of wet
bone tissue [23].
1.3 Challenges to Bone Tissue Engineering Approaches
Although much progress has been made in the field of tissue engineering, critical
barriers such as lack of scaffold vascularization, the host inflammatory response, and the
need to use high doses of growth factors to differentiate cells must be overcome in order
to effectively create functional tissues. In dealing with vascularization, tissue engineering
meets a mass transfer challenge, which limits scaffold construct size in vivo regardless of
tissue specific goals. The majority of cells are situated within 100-200 microns [26] of
capillaries where sufficient oxygen and nutrition is provided and metabolic waste is able
to be transported [27]. It is difficult to engineer scaffolds less than a few hundred
microns thick, therefore the ability for angiogenesis to occur in large scaffolds becomes a
critical consideration.
Another important factor is translating in vitro success to in vivo applications by
accounting for the host immune response to implanted biomaterials that can lead to graft
rejection. This reaction protects the body from harmful intruders and is beneficial on
small time scales, but chronic inflammation can interfere with tissue engineering
approaches to repair damaged tissue. The complicated interplay of cells and cytokines at
the interface of an implanted biomaterial that governs success versus failure of an implant
is still difficult to understand, but must be deconstructed in order to properly design an
approach to harness inflammation and promote wound healing.
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After a biomaterial is inserted into the host tissue, a sequence of reactions occur
(Figure 1.1). First, injury to the vasculature causes blood to contact the material. Proteins
from the serum bind to the implanted biomaterial and form a provisional matrix
composed of fibrin, platelet granule components such as thrombospondin, transforming
growth factor alpha (TGF-α) transforming growth factor beta (TGF-β), platelet-derived
growth factor (PDGF), platelet factor 4 (PF4), and platelet-derived endothelial cell
growth factor (ECGF1) [28]. Monocytes exit the capillaries, attach to the matrix that has
formed on the biomaterial surface, and differentiate into pro-inflammatory M1
macrophages. M1 macrophages release cytokines such as tumor necrosis factor alpha
(TNF-α), interleukin-1 beta (IL-1β), interleukin-6 (IL-6), and monocyte chemotactic
protein 1 (MCP-1) that drive the acute inflammation response [29, 30]. The next event in
the host response to an implanted biomaterial is chronic inflammation, which is defined
by the presence of macrophages, monocytes, lymphocytes, blood vessel proliferation, and
connective tissue formation [31-34]. Foreign body giant cells and macrophages will
generally exist at the tissue-implant interface for the duration of the biomaterial’s lifetime
[35-39]. A fibrous capsule usually forms around the foreign body reaction, separating the
biomaterial from the host tissue [28]. In some tissue types, acute inflammation stimulates
M1 pro-inflammatory macrophages to change phenotype into wound healing M2
macrophages. This polarization from M1 to M2 is a critical component of avoiding graft
and biomaterial rejection.
Several approaches have been taken to control host inflammation in response to
implanted biomaterials such as casing the scaffold with biocompatible coating,
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incorporating anti-inflammatory pharmaceuticals in the substrate, and releasing
angiogenic growth factors at the site of graft insertion. Biocompatible material coatings
generally rely on creating a hydrophilic boundary between the implant and the host tissue
[40, 41] which lessens the immune response, and subsequently maintains functionality of
the implant for a slightly longer time period than an unmodified substrate [42-44].
Natural and synthetic polymers are typically used for this process, however, natural
polymers can be immunogenic, decompose quickly at elevated temperatures that are
necessary in manufacturing processes, and can exhibit much material inconsistency [41].
On the other hand, synthetic polymers offer the ability to tune the material specifically
for the application, but generally have low adhesion capabilities for binding to the
biomaterial, low mechanical strength, toxic chemicals are usually used to crosslink the
polymer, and synthetic polymers present biocompatibility issues [41, 45]. Another wellutilized method of promoting implanted material success is to induce angiogenesis using
vascular endothelial growth factor (VEGF) [46-48]. Although somewhat successful, this
method can overexpose tissues to growth factors which can cause arthritis or tumor
formation [49-51]. Additionally, angiogenic growth factor release is not effective since
multiple signals are required in the neovascularization cascade and temporal release of
the cytokines is difficult to control. Anti-inflammatory drugs inhibit secretion of
inflammatory mediators like leukotrienes and prostaglandins, reduce the amount of
inflammatory cells, and lessen fibroblast recruitment at the site of implantation [52].
These drugs are typically administered systemically, therefore a drawback of this method
arises with unwanted side effects occurring throughout the body [53]. Furthermore, anti-
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Figure 1.1 Inflammation cascade after implantation of a biomaterial. 1) Biomaterial is implanted, and 2)
proteins from the disrupted capillaries adsorb to the biomaterial surface. 3) Monocytes that are
circulating in the vasculature migrate to the site of implantation, and 4) differentiate into M1
macrophages. 5) M1 macrophages are pro-inflammatory and initiate the host inflammation response by
6) releasing cytokines to 7) recruit fibroblasts for fibrous capsule formation.

inflammatory drugs such as corticosteroid drugs downregulate VEGF, thus inhibiting
new blood vessel formation necessary for nutrient exchange in the implanted tissue [54,
55].
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CHAPTER 2: CELL SOURCES FOR TISSUE ENGINEERING
2.1 Introduction
Choosing the correct cell type as part of a tissue engineering approach to create a
functional bone graft substitute is essential for success of the implant. Cell types such as
lineage committed progenitor cells, adult stem cells, and pluripotent stem cells all present
viable options. Cell type selection is an important factor to consider, as cells seeded on
scaffolds may stimulate signaling events that trigger host cells to migrate and integrate
with the newly formed tissue, thus accelerating wound healing process following scaffold
implantation.

2.2 Progenitor Cells
Progenitor cells are lineage-committed and maintain the tissue in which they
reside [56]. These progenitor cells have been discovered in muscle tissue [57], cartilage
[58], bone [58, 59], tissue in the central nervous system [60], in the bulge of the hair
follicle [61], as well as many other locations. Like human mesenchymal stem cells
(hMSCs), progenitor cells have a finite limit to proliferation and follow Hayflick’s limit
of 50-70 population doublings [56, 62]. Progenitor cells have the advantage of patient
specific treatment, however their narrow differentiation capabilities and limited
proliferation potential present severe drawbacks.
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2.3 Adult Stem Cells
Numerous studies have demonstrated the potential of human mesenchymal stem
cells in bone tissue engineering applications [63-68]. While they eliminate the
controversy surrounding human embryonic stem cells (hESCs), they also present
disadvantages such as the loss of proliferation capabilities with increasing passages and
their infrequency in the stroma indicates a limited population of cells that can actually
differentiate into osteogenic lineage [69, 70]. Studies conducted in animal models
demonstrated that the amount of bone formed from hMSCs was insufficient to bridge a
large bone defect [71]. Another shortcoming with using hMSCs for tissue engineering
studies is that multipotency limits their differentiation potential to specific cell types [73,
74]. However, when exposed to the correct chemical signals, adipose-derived hMSCs
(AD-hMSCs) can differentiate towards osteogenic, chondrogenic, adipogenic, myogenic,
and hepatic lineages, as well as become endothelial cells [75-78]. Bone marrow-derived
hMSCs (BM-hMSCs) are a type of adult stem cell that can differentiate to bone,
cartilage, muscle, ligament, tendon, adipose, and stroma lineages [79-82]. Although
hMSCs have disadvantages, their ability of patient-specific treatment and differentiation
capabilities into osteogenic lineage offer immense potential for use in bone tissue
engineering strategies.
2.4 Embryonic Stem Cells
Both human mesenchymal stem cells and human embryonic stem cells have been
investigated as a source of new bone tissue for grafts. hESCs possess the unique ability to
self-renew and have the potential to differentiate into any cell type formed from the three
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germ layers [83, 84]. hESCs offer a promising tool for biomedical research as they can be
used in developmental studies, disease modeling, drug testing, and regenerative medicine
[85]. These stem cells are derived from the inner cell mass of a pre-implantation embryo
during the blastocyst stage [86-88]. The maintenance and culture of hESCs usually
involves growing cells in feeder-dependent or feeder-free conditions, and cells are kept in
colonies in order to preserve an undifferentiated state. Embryoid bodies (EBs) are
commonly used to mimic the three-dimensionality of development during gastrulation
and the formation of the three germ layers in vivo [89]. The limitation of employing EBs
for differentiation studies arises from the fact that the yield of desired cells is much lower
than the initial amount of cells [90]. In order to use hESCs for differentiation
experiments, cells must retain pluripotency and self-renewal capabilities, and it is
imperative to parse the underlying developmental mechanisms involved in osteogenesis
in order to successfully engineer bone tissue.
hESCs are promising candidates for bone tissue engineering applications since
they can differentiate into every cell type found in bone [91-96]. Osteoblasts, osteoclasts,
nerve cells, and vascular cells all contribute to bone architecture and function, and given
the correct signals, hESCs will become these cell types [97]. hESCs are a superior choice
for bone tissue regeneration strategies based on their pluripotency and proliferation
capabilities, but they offer obstacles to overcome as well.
hESCs are difficult to culture and scaffold surface modification is required for cell
attachment; substrates traditionally have been coated with protein cocktails such as
Matrigel or Geltrex to promote cell adhesion. Bone-forming osteoblast cells or
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osteoprogenitor cells can also be used to deposit natural extracellular matrix proteins onto
the substrate for hESC attachment. To date, great strides have been taken in using native
bone components to create scaffolds to promote the growth of osteoblast-like cells,
however most approaches focus on one element of the ECM as opposed to the entire
network [98-107]. Decellularized scaffolds composed of the organic and inorganic
elements of bone ECM are osteoinductive as well as osteoconductive. The interactions
between cells and the ECM have the ability to define cell development and function
[108]. By using osteoblasts to deposit ECM, a natural bone microenvironment is created
that will stimulate hESCs to differentiate into osteogenic lineage. Although numerous
studies have shown the potential of decellularized scaffolds, there is a lack of
characterization of the signals involved in using natural ECM to direct the differentiation
of hESCs and there is a need for determining which spatial and temporal cues control the
diverse development of bone.

2.5 Induced Pluripotent Stem Cells

Induced pluripotent stem cells (iPSCs) were first created by introducing four
pluripotency transcription factors (Oct3/4, Sox2. C-Myc, and Klf4) to a mouse fibroblast
cell, after which the fibroblast exhibited properties of undifferentiated hESCs [109].
These stem cells have the ability to differentiate into cells of all three germ layers, can
self-renew, and proliferate indefinitely [110, 111]. Unlike hESCs, iPSCs offer the
opportunity for patient specific treatment since somatic cells can be taken from the target
host, reprogrammed through the addition of transcription factors, cultured to increase cell

12

number, differentiated towards the desired lineage, and finally implanted back into the
patient. Since the genetic material in the implanted cells is the same as in the host’s cells,
the risk of immunorejection is low.
One obstacle with using iPSCs for tissue engineering approaches is that this cell
source uses a viral vector to introduce the pluripotency transcription factors to the stromal
cell. This has raised concern regarding unwanted side effects in patients, even though the
vector portion is composed of just the viral envelope. Another barrier for using hESCs
and iPSCs in regenerative medicine is that teratoma formation in implanted tissue can
occur when cells have not fully and uniformly differentiated into the target tissue [112,
113]. Therefore, it is extremely important to develop a direct approach to exclusively
generate desired cells in order to avoid spontaneous teratoma formation.

13

CHAPTER 3: METHODS TO RECAPITULATE IN VIVO MICROENVIRONMENT
3.1 Cell-ECM Interactions Determine Cell Phenotype

Although hESCs, iPSCs, and hMSCs are promising cell sources for tissue
engineering applications and invaluable tools for studying developmental biology, there
are still many fundamental aspects of stem cell biology that are unknown. Specifically,
researchers are striving to understand and deconstruct the mechanisms by which the
microenvironment effects lineage determination, as well as cell phenotype and function.
The native microenvironment is composed of the ECM, which is a network of
proteins that provides physical and chemical cues determining cell behavior [114-117].
Cell biologists have analyzed numerous cytokines and soluble factors responsible for
stem cell regulation, however, recent studies indicate that these soluble factors work in
conjunction with the insoluble components present in the ECM such as adhesive,
mechanical, and topographical cues [118-122]. Specifically, insoluble factors are made
up of collagens, non-collagenous glycoproteins (laminin, elastin, fibronectin), and
hydrophilic proteoglycans [123]. Stem cells can detect and respond to signals
simultaneously presented in the microenvironment; cell mechanotransduction machinery
converts these soluble and insoluble cues to signal upregulation of various genes and
subsequent lineage commitment [122].
Past biomaterial design has focused on microscale technologies to drive stem cell
lineage commitment, but the in vivo tissue structure also provides cues to cells at a
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nanoscale level. Furthermore, cells tend to respond to some microscale fiber scaffolds the
same way that they do when cultured on a 2D polystyrene cell culture plate. Cell
morphology becomes flat, which causes a lopsided attachment of focal adhesions [123].
Therefore, for certain tissue engineering approaches to generate softer tissues, providing
signals at the microscale level might be physiological inconsistent for directing stem cell
differentiation [124]. There is a need to engineer functional nanoscale microenvironments
for tissue engineering applications. The field of nanotechnology in relation to tissue
engineering involves designing novel materials with at least one dimension between 1100 nm to use as scaffolds for influencing cell behavior [125]. Section 3.5 will discuss
different techniques for creating biomaterials with nanoarchitectural features.
Nano and microscale signals such as shear stress, strain, material elasticity,
topographical variation, and cell shape all affect cellular function and lineage
specification. Cells experience mechanical cues such as stress and strain in the in vivo
microenvironment. Muscle contraction and relaxation, bone compression and
decompression, cell migration, fluid flow, and tissue regeneration all cause variations of
mechanical forces in the body. The ECM also has a range of elastic moduli that generate
physical stimuli for attached cells through focal adhesions. These mechanical cues are
transduced through focal adhesion kinase (FAK) and Src family signaling [122].
Furthermore, integrins are activated by stress, strain, and differing elastic moduli. This in
turn increases focal adhesion strength and upregulates integrin mediated signaling
throughout the cell. The biochemical pathways that are activated as a result of physical
stimuli are part of a positive-feedback loop which further activates actomyosin
cytoskeleton tension and increases focal adhesion strength [122, 126, 127]. As a result,
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researchers have explored how varying signals alter hESC behavior in vitro with hopes of
determining what physical forces, separately or in combination, control lineage
commitment.
The effect of mechanical cues on cell function has been reviewed for many cell
types, and has established general knowledge regarding cell behavioral responses [121,
128-131]. Recent studies have made great strides in determining the impact physical
stimuli have on hESCs. For example, the effect of cyclic strains on hESCs inhibited
differentiation and increased self-renewal [132]. This was caused by the upregulation of
TGFβ1, Activin A, and nodal which initiates the phosphorylation of Smad 2/3 [133].
Another study showed that cyclic stress through integrin-mediated adhesions induces
spreading of mouse ESCs and decreased the expression of pluripotency marker Oct3/4
[134].
Shear flow has also been investigated as a mechanical cue for ESCs since it is a
dynamic stress found in vivo, most commonly exerted on cells in the circulatory system
[135]. Mouse ESCs placed in a microfluidic chamber demonstrated that a higher flow
rate of 1.1 μL/min produced larger, round colonies as compared to slower rates of 0.001
μL/min and 0.019 μL/min [136]. This rounded phenotype indicates decreased
cytoskeletal tension. When ESCs are subjected to highly controlled shear flow they
differentiate into endothelial or specialized cardiovascular cells [137, 138]. Furthermore,
ESCs exposed to culture conditions with shear stress express greater levels of endothelial
cell proteins CD31 and Runx1, and cells formed hematopoietic colonies [139].
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Figure 3.1 Biomaterials with (a) fibrous architecture, (b) surface roughness and
varying nanotopographical features, and (c) nano grooves/ridges provide cues to
cells. These microenvironmental signals, along with other mechanical cues
mentioned in this review, have the ability to cause cell migration, adhesion,
differentiation, proliferation, and alignment.

17

3.2 Material Properties Influence Cell Behavior
A recent study demonstrated that matrix elasticities of 1 kPA, 8 kPa, and 25 kPa
lead hMSCs respectively towards neurogenic, myogenic, and osteogenic lineage [131].
This discovery, along with the known fact that matrix mechanics are a definitive factor in
tissue morphogenesis and cell function [140-142], influenced researchers to investigate
the response of ESCs to material properties.
ESCs are generally cultured on stiff 2D cell culture plates. Studies have shown
that cell traction and colony stiffness increase when ESCs are grown on traditional rigid
substrates, which also correlates with the downregulation of Oct3/4 in mouse ESCs [134,
143]. Cells grown on soft polyacrylamide gels with a stiffness of 0.6 kPA formed round,
compact colonies that had high Oct3/4, Nanog, and Alkaline Phosphatase expression
compared to the polystyrene plates with stiffness of approximately 4 MPa [143]. This
study demonstrated that soft materials cause cells to exhibit low traction forces and
colony stiffness, and as a result, self-renewal and pluripotency of ESCs is maintained.

3.3 Cell Shape Governs Phenotype
Stem cell shape regulates physiology, controls proliferation, and ultimately
governs lineage specification [144, 145]. Cells have particular shapes that optimize
carrying out specific cellular functions: neurons have long bodies to efficiently deliver
signals that can span the entire length of the human figure, where adipocytes are spherical
to store lipids [122]. From a developmental point of view, signals from the stem cell
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niche induce conformational changes which then influence tissue structure and purpose
[146-148].
One of the first experiments demonstrating the impact of cell size on behavior
used 20 μm2 and 75 μm2 fibronectin islands to show that size directly controls apoptosis
and proliferation, respectively [149]. Furthermore, studies have shown that restricting
hESC colony size regulates differentiation, with smaller cell groupings favoring
endoderm commitment over ectoderm [150]. Patterning adhesive ligands to control hESC
colony size determined large colonies with a high cell density microenvironment promote
pluripotency, controlled through a BMP-mediated Smad1 gradient. This gradient forms
due to the interaction of hESCs and hESC-derived extraembryonic endoderm [151].
These findings are thought to occur due to cell-cell contact, varying mechanical stresses
throughout the body of cells, and soluble factor gradients.

3.4 Substrate Topography Provides Important Cell-ECM Signals
Topography plays a key role in cell maintenance and function. Nanoscale
architecture has grooves, ridges, pits, and pores in vivo; for example proteins in the ECM
are generally arranged in a fibrous manner with these topographical properties. These
fibrillar networks are approximately 10-100 nanometers but can be several microns [152,
153], and the bone marrow contains numerous nanoscale pores that provide additional
cues for stem cells [135]. Nanotopography is important because cells receive signals
through specific binding sites that integrins recognize, and integrin signaling is controlled
through nanoscale ECM-cell interactions [124]. Surface features as small as 10 nm have
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the ability to influence cell adhesion [154]. When cells bind to integrins, tyrosine kinase
and phosphatase signaling is activated, and both are important for cell fate and gene
expression [122]. Through these biophysical cues, stem cell adhesion and cytoskeleton
organization are regulated, thus cell decisions regarding proliferation, migration,
elongation, cell alignment, polarization and differentiation are impacted [152, 155-162].
Studies using MSCs determined that the nanoscale topography potentially acts through
spatial control of ligands and regulatory factors, and the interplay between physical and
biochemical cues determine cell morphology and phenotype [135]. This, among other
principles discovered by examining hMSC response to alterations in topography, can be
applied to human pluripotent stem cells (hPSCs).
Topography is a powerful tool since, not only is cytoskeleton tension altered like
in cell shape experiments, but entire molecular arrangement and dynamic organization of
cellular adhesion mechanisms are effected [122]. Polymethylglutarimide (PMGI)
nanofibers were used as scaffolds to maintain mouse ESC stemness and it was concluded
that fiber density and structure were important factors in retaining pluripotency. This
study also found that mouse ESCs had the ability to differentiate into all three germ
layers on this substrate [163]. Studies observing the response of hESCs to
nanotopography have used fibronectin coated poly(di-methyl siloxane) (PDMS)
substrates with 600 nm ridges, 600 nm spacing, and 600 +/- 150 nm height. Single cells
were placed on the surface for 24 and 48 hours, and it was determined that the
nanotopographic surfaces increased cell alignment and elongation, but decreased
projected cell area and proliferation [164]. An experiment utilizing polyamide
nanofibrillar surfaces covalently linked to FGF-2 found that this substrate enhanced
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hESC proliferation [165]. The use of fibrillar nano architecture in scaffolds has the
potential to spatially align and organize cells while retaining pluripotency, however cell
proliferation capabilities depends on the ridge size and surface chemistry of the scaffold
and must be further optimized to sustain hPSC growth.
Another study used UV-assisted capillary force lithography to create 350 nm
ridge/groove pattern arrays, then demonstrated the ability of the surface topography to
direct hESCs towards neuronal lineage in the absence of differentiation-inducing soluble
factors [166]. Furthermore, neural differentiation of ESCs was demonstrated in an
experiment using poly(L-lactic acid) (PLLA) electrospun nanofibers incorporated with
single wall carbon nanotubes (SWNTs) and multi wall carbon nanotubes (MWNTs).
Scaffolds containing the carbon nanotubes promoted greater differentiation towards
neural lineage, shown by an upregulation of Map-2. Differentiated cells aligned on the
fibers demonstrating the influence of physical cues on cell morphology and lineage
commitment [167]. Another recent study also investigated the effects of topography on
human iPSC differentiation towards neuronal lineage [168]. A PDMS substrate was
patterned with ridges/grooves of width 350 nm and groove depth of 300 nm, then single
cells were placed on the nanostructures and allowed to differentiate for 4 days. Cell
alignment on the 350 nm width groove substrate was compared to surfaces with 2 μm and
5 μm widths, and it was found that cells responded with the highest degree of alignment
to the nanogrooves. Additionally, human iPSCs placed on the 350 nm substrate expressed
the highest levels of neuroectodermal markers NPY and SYT4, demonstrating the
importance of topography in guiding pluripotent stem cell phenotype. Collectively, these
results indicate that controlling hPSC alignment on nanogroove structures directs cell
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differentiation towards neuronal lineage, and ESCs on random electrospun fibers
incorporated with carbon nanotubes will purposefully elongate with the direction of the
fibers and upregulate neuronal marker gene Map-2.
MWNT films were employed to investigate the response of hESCs to surface
roughness. hESC colonies favored rougher surfaces for attachment, exhibited flattened
morphology with standard colony size, and retained pluripotency when cultured on
MWNT films [169]. A similar study grafted CNTs with poly(acrylic acid) (PAA) to
form a thin film, and the results indicated that this substrate, in combination with neural
growth factors, stimulates hESC differentiation towards neural lineage at a higher rate
than a conventional poly-L-ornithine (PLO) substrate often used in generating neurons
from stem cells [170]. Another study utilized an array of CNTs conjugated with ECM
proteins to determine the hPSC behavioral response when cultured on this platform. This
array was found to support undifferentiated hESC and iPSC growth as well as selfrenewal and pluripotency marker expression [171]. Furthermore, it was shown that both
types of hPSCs cultured on the CNT arrays were able to differentiate towards ectoderm,
mesoderm, and endoderm lineages [171]. The hPSCs grown on the CNT arrays were then
directed towards spontaneous differentiation, and in reaction to the CNT topography,
preferentially expressed mesodermal markers due to the physical stimuli exerted on the
cells [171]. A similar study investigated culturing hESCs on a collagen/CNT matrix.
Colonies were placed on tissue culture plates coated with gelatin, collagen, and
collagen/CNTs and allowed to spontaneously differentiate. Colony morphology on the
gelatin substrates was random and spread out, while hESCs on the collagen as well as the
collagen/CNT matrices exhibited an elongated shape that aligned with the fibrils. By day
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3, hESCs on the collagen/CNT surface expressed the early neural progenitor marker
nestin significantly higher than the cells on the collagen substrate. By day 6, all three
groups expressed nestin, with the highest levels detected in the collagen/CNT group
followed by the collagen and gelatin groups, respectively [172]. These groundbreaking
studies involving CNTs have provided insight on stimuli controlling hPSC lineage
specification. CNT films maintain hPSC pluripotency and undifferentiated colony
phenotype, substrates containing fibrillar architecture with CNTs promote hESC
differentiation towards neural lineage, and CNT arrays exert physical forces on hPSCs
that guide them towards mesoderm lineage commitment.
In another study, surface nanoroughness of silica-based glass wafers was altered
and hESCs were placed on the various substrates in single cells. hESCs on the control
glass surface demonstrated highly branched morphology with many cytoplasmic
extensions, while cells on the nanorough glass were compact with few, short filapodia.
Cells on a rough surface patterned with square-shaped smooth islands favored attachment
to the smooth glass instead of the nanorough areas and expressed pluripotent marker
Oct3/4, and hESCs placed on an exclusively rough surface spontaneously differentiated.
Proliferation of hESC colonies was determined by placing cells on smooth glass and
nanorough substrates, and it was determined that doubling time of hESCs on the control
surface was 41 hours compared to a slower 71 hour doubling time of colonies on the
rough surface [173]. In opposition, a study showed that silica colloidal crystal with
diameters of 120, 400, and 600 nm coated with collagen I maintained the expression of
murine ESC markers in comparison to smooth glass. However, colonies exhibited
reduced spreading on the surface with altered topography [174]. Another study coated
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cell

culture

plates

with

poly[2-(methacryloyloxy)ethyl

dimethyl-(3-

sulfopropyl)ammonium hydroxide], then demonstrated that hESC colonies cultured on
this substrate maintained their proliferation, self-renewal, and pluripotency capabilities
[175]. A unique study used graphene and graphene oxide to coat glass coverslips and
observed mouse iPSC behavior on the different substrates. It was found that iPSCs on the
graphene and smooth glass surfaces proliferated at similar rates, but cells on the graphene
oxide substrate had greater adhesion and proliferation. The graphene substrate maintained
cells at an undifferentiated state, while the graphene oxide surface promoted spontaneous
differentiation [176]. Overall, rough surfaces promote PSC adhesion with a more
compact morphology, however, studies have found opposing evidence for whether or not
nanorough surfaces maintain pluripotency and an undifferentiated state, or promote
spontaneous differentiation. There are also conflicting results determining if these
surfaces foster or hinder proliferation, therefore more studies are warranted to understand
how PSCs respond to rough culture substrates.
3.5 Nanoscale Technologies
The in vivo microenvironment is composed of channels, pores, and ridges that
provide physical cues to cells at a nanoscale level [124]. Knowledge of how these factors
influence stem cell behavior is necessary to effectively design scaffolds that differentiate
stem cells to the desired lineage. To analyze the impact of nanofeatures on cell behavior,
engineers and scientists have combined principles of chemistry, physics, material science,
and biology to create specialized substrates. Fabrication techniques such as soft
lithography, deposition of nanostructures, microfluidics, and electrospinning all create
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ways for researchers to manipulate topography [177-179]. These platforms have been
used to determine specific cues that regulate stem cell function.
Electrospinning is a technique that can form a network of polymer fibers down to
the size of 10 nm [180]. To generate electrospun scaffolds, a voltage is applied to a
polymer solution, the charged solution is ejected though a needle, and electric forces
stretch the polymer jet so that fibers with submicroscale diameters form on the grounded
collector surface [181]. Since the fiber diameters are much smaller than cellular surface
area, this platform allows cells to organize around the fibers [182] and attach with a
spread morphology with numerous focal adhesions [183]. Another advantage of this
technique is the ability to create electrospun scaffolds from synthetic as well as natural
polymers [181]. However, one challenge with this fabrication method is that cells cannot
migrate throughout the scaffold due to pore sizes being smaller than that of a cell [123].
Recent progress has overcome this limitation by using self-assembly of nanofibers
around the cells [184]. Knowledge of protein self-assembly and optimization of
noncovalent intermolecular interactions produced this revolutionary approach to forming
the nanofibrillar architecture around cells without damaging them [185, 186]. This
technique allows the scientist to spatially and mechanically organize cells, which is
critical to tissue engineering strategies since cells in the body are arranged in specific
patterns that form tissues and organs [123]. This fabrication process is able to create
substrates that mimic grooves, ridges, and the fibrillar ECM structure, and recent
advancements with assembling the scaffold material around target cells has overcome the
previous inability of cells to infiltrate the scaffold.
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The general method of soft lithography uses elastomeric stamps to print nanoscale
polymers on a surface [187-190]. Patterned polymers can range from 30 nm to several
microns [191]. This is a useful technique because the engineer has full control over
spatial distribution of polymer molecules placed on the substrate, which subsequently
determines cell spreading and shape [192-194]. Soft lithography is an invaluable tool
because it creates a platform on which researchers can isolate and control mechanical
cues exposed to single cells [195] and also pairs or triplets of cells [196]. This technique
is very useful in deciphering cellular reactions to individual physical cues since the
polymers can be easily manipulated to express specific mechanical characteristics.
However, a limitation with this platform is that soft lithography is only able to provide a
narrow range of ECM signals for the cell to receive, which is inconsistent with the many
microenvironmental cues provided to cells in vivo.

Hydrogels are a popular tissue engineering scaffold with proven success in
medicine and biological research due to their tunable tissue-like properties [197-201].
The goal of hydrogel design is to mimic natural ECM, which is accomplished by
crosslinking polymers. The intricate linking of these hydrophilic molecules forms a
network with tissue-like viscoelastic mechanical properties, as well as similar interstitial
flow to the in vivo microenvironment. Similar diffusive transport also occurs in hydrogel
cell culture platforms, and hydrogels can be designed to incorporate cell adhesion ligands
and other biologically relevant components [123]. Although hydrogels are an extremely
moldable substrate and offer numerous advantages as scaffolds for tissue engineering,
they have low mechanical strength, they are difficult to sterilize, and loading drugs and
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cells in the matrix before crosslinking the material is difficult [202, 203]. Further
optimization studies are warranted to overcome these barriers.
Carbon nanotubes possess ideal qualities for tissue regeneration strategies such as
tunable chemical and mechanical properties, electrical conductivity, cytocompatibility,
and nanoscale dimensions that serve as topographical cues [204]. Furthermore, CNTs
have numerous applications for directing cell behavior such as drug delivery, gene
modifications, and incorporation in the in vitro 3D cell microenvironment to add
roughness [205-207]. When placed in fetal bovine serum (FBS), proteins readily adsorb
to the surface of CNTs subsequently promoting cell attachment [208]. Several studies
have demonstrated the potential of CNTs for bone tissue engineering applications [209212], myoblastic cell attachment and growth [208] as well as neuronal cell proliferation
[213], but little is known regarding the effect of CNTs on stem cell fate. In order to
hypothesize how CNTs could influence pluripotent stem cell behavior, an analysis of
studies conducted on the effect of CNTs on other cell types must be done, with further
scrutiny on how individual characteristics of CNTs control the cellular response. Towards
this goal, a recent study has shown that the mechanical properties of CNTs promote
differentiation of MC3T3-E1 osteoblasts towards osteogenic lineage [209]. A study
isolating the conductivity attribute of CNTs demonstrated that multiwall carbon
nanotube-incorporated hydrogels increased cell proliferation of myocytes as well as
fostered the growth of multinucleated cells with higher actin filament interactions as
compared to the control groups [214]. CNTs can be functionalized to exhibit varying
chemical properties that influence cell phenotype, shown in a study investigating single
wall carbon nanotube conjugation with poly(m-aminobenzene sulfonic acid) and
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poly(ethylene glycol) in which neurons exposed to more positively charged groups
exhibited greater neurite length and had additional growth cones [215]. Since CNTs
exhibit numerous traits that have the potential to impact cell lineage commitment, there is
a need to delineate the effects of each specific CNT characteristic on hPSC behavior.

Microfluidics allows for precise regulation of fluid flow and microenvironmental
geometry, usually in the form of channels with similar dimensions to that of the cell type
under investigation. Volumes can easily be controlled to levels of 10-18 liters [216], and
the flow rates are manipulated so that shear stress in the in vitro microenvironment is
optimized. Microfluidic platforms have been used extensively to study cell biology,
specifically cellular adhesion forces [217], the cytoskeleton [218], and the culture of
embryos [219-221]. This platform is useful in determining the influence of shear stress on
individual cells, as well as mimicking the effects of capillary and interstitial flow, but the
scale of this technique is not practical for larger magnitude tissue regeneration studies.

3.6 Microscale Technologies
Cellular scaffolds mimicking tissue generally have large, macroscale features that
promote cell adhesion, migration, and proliferation. However, microscale features are
needed to allow vascularization of thick tissue requiring higher levels of oxygen diffusion
than connective tissues, such as the skin [222, 223], bladder [224], and the cornea [225,
226]. By altering the physical topography of 3D scaffold structures, cell function can be
controlled through a variety of means such as cell-cell contact, cell morphology, and cell
orientation [227, 228]. Micro-fabrication of vascular networks for scaffolds is generally
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achieved using methods such as photolithography, 3D printing, and soft lithography
[229-238]. The approach behind these methods is to allow oxygen into deeper portions
of the developing tissue to stimulate in vitro vascularization and more efficient nutrient
exchange.
Photolithography is a highly utilized approach to creating substrates for tissue
engineering strategies. This method creates micro-patterned scaffolds through the use of a
photomask, which is an opaque plate that allows light to pass through only at specific
transparent points that are composed of patterns [239-243]. This approach uses prepolymers that crosslink when exposed to UV light, a photomask, and a photoinitiator.
When the pre-polymer is placed under the photomask, only pre-polymer that is below the
transparent regions is crosslinked, polymerized, and therefore patterned through light
exposure. The photoinitiator catalyzes the reaction of the pre-polymer with the UV light,
and is ideally nontoxic to cells. Micro-patterning hydrogels such as poly(ethylene glycol)
[244-247], methacrylated hyaluronic acid [248-251], and gelatin methacrylate [252, 253]
has been successful in tissue engineering approaches. In a recent study [244], bio-active
poly(ethylene glycol) diacrylate (PEGDA) was micro-patterend with adhesive ligand
RGD in various concentrations and geometries. Endothelial cells were cultured on the
substrates and cells formed cords resembling capillaries on 50 µm wide strips of RGD.
Furthermore, cells formed cords at an RGD concentration of 20 µg/cm2, but did not
arrange in this manner at higher RGD concentrations. Photolithography is a powerful yet
simple tool for studying tissue morphogenesis. The fabrication process is straightforward
and provides a method to study cellular phenotype in response to microscale structures.
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3D printing, or rapid prototyping, is a relatively new method of creating three
dimensional objects. Rapid prototyping is an approach to fabricate 3D structures from
model data usually using a layer-by-layer approach. These processes generally follow a
similar pattern including the initial computer aided design (CAD) model of the part,
conversion to an appropriate file format, slicing the file into thin layers for deposition,
and the final layer by layer construction phase. CAD programs such as SolidWorks or
AutoCad are used in the first step to create the customized part for manufacture, and then
CAD files are converted to the standardized STL file format. The initial study that
started the rapid prototyping methods was Charles W. Hull in 1986 who patented
stereolithography (US Pat. 4,575,330). This method utilizes a layer-by-layer technique to
building 3D models with photolabile polymers, or resin, that are cured when exposed to
UV light. This happens with a platform that is submerged in a container of uncured resin
slightly below the platform. A focused UV laser then traces out the first cross section
leaving the remaining tray of resin in liquid form. The platform slowly moves down
leaving the laser to trace each cross section of the part until a fully cured part remains.
This approach has been used for hard tissue applications [232] as well as soft tissue
applications [254-256]. For a soft tissue study [254] a group used poly(ethylene glycol)
hydrogels at differing PEGDA concentrations and laser energies for use in determining
hydrogel thickness. These hydrogels were used to study encapsulated cell viability in
fabricated 3D PEGDA structures, which showed at least 87% viability after 24 hours,
thus proving that rapid prototyping is a viable option for soft tissue engineering.
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As mentioned in section 3.5, soft lithography is a valuable tool in the in the field
of tissue engineering with capabilities for duplicating nanometer to micrometer
structures. This is accomplished using stamps, molds, and photomasks. Furthermore, soft
lithography can be combined with microfluidic methods for vascular tissue engineering
strategies. This approach uses soft lithography to create branched networks mimicking in
vivo vasculature, seeds cells on the substrates, and connects the system to a microfluidic
perfusion bioreactor to replicate shear stress [257]. Furthermore, 3D vascularized
scaffolds have been created by using a layer by layer microfluidic approach [237, 258,
259]. Microfluidic channels have been generated using polymers such as PDMS, PLGA,
and PGS, and endothelial cells are cultured on these substrates for vascular engineering
approaches [229, 260, 261]. This is a precise technique to stimulate the formation of
capillaries in a way that replicates in vivo structures. A recent study used soft lithography
techniques to pattern non-adherent agarose templates in order to recapitulate early actions
of angiogenesis [262]. Human mesenchymal stem cells and human umbilical vein
endothelial cells were placed on these substrates, and VEGF expression was monitored as
a means of determining mechanical impacts of the microenvironment on angiogenesis.

3.7 Scaffold Design for Bone Tissue Engineering
Tissue engineering presents a new avenue for developing bone grafts by
combining the use of cells, specific signaling molecules, and three-dimensional (3D)
substrates [263-266]. Recent efforts towards developing bone graft substitutes focus on
3D scaffold design. The 3D matrix should mimic the structure of bone, in which porosity
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and mechanical strength are important characteristics. A scaffold should also guide the
integration of host cells, the differentiation of transplanted cells, and promote bone ECM
formation on the surface of the substrate [267]. In this spirit, biodegradable scaffolds
provide a temporary matrix for cells to attach, proliferate, and deposit ECM [268-272].
Polymers such as poly(lactic acid) (PLA), poly(glycolic acid) (PGA) and their
copolymers poly(lactic-co-glycolic acid) (PLGA) have demonstrated success in bone
tissue engineering applications due to their biocompatibility, osteoconductivity, and
mechanical properties [273-277]. Various scaffold fabrication methods used in tissue
engineering studies include phase separation [278], freeze drying [279], solute leaching
[280] and gas foaming [281]. Newer methods such as electrospinning [282] provide a
porous structure, and this technique as well as 2D patterning are becoming increasingly
popular in scaffold design. The phase separation technique utilized in this presented work
is depicted in Figure 3.2.
Towards this effort of directing cell behavior, various biomaterials as well as
different cell types and signaling molecules have been investigated. Recent studies have
examined the ability of mechanical signals to influence stem cell lineage commitment
since cells in the body reside in different tissue niches with variable mechanical
properties that effect cellular function. From this information, biomaterials have been
designed to harness tissue-specific mechanical properties to guide stem cells to the
targeted cell type. Specifically, 3D platforms with nano and microscale features are
utilized since they offer a unique ability to mimic the physical cues that cells receive
from their microenvironment. Researchers have developed materials with tunable matrix
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Figure 3.2 Fabrication of PLGA microsphere-sintered scaffolds. A mixture of 1:4
PLGA dissolved in dichloromethane is slowly poured into a 1% Poly(vinyl alcohol)
solution stirred at 330 RPM (1). Microspheres are stirred for 24 hours, then collected
via vacuum filtration (2). After a lyophilization step, microspheres are sorted
according to size by using a micron sieve (3). Microspheres are placed in stainless
steel molds to form scaffolds (4), and heated for 4 hours at 85 °C to sinter (5). Final
scaffolds are 10 mm in diameter and 2 mm in height (6).
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elasticities, nanotopographies, and nanoscale patterns that have the ability to manipulate
cell phenotype.
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CHAPTER 4: DESIGN OF AN OSTEOMIMETIC SCAFFOLD FOR
ENHANCED HESC DIFFERENTIATION
4.1 Introduction
Scaffold design is a crucial component in bone tissue engineering strategies. The
ideal scaffold should provide a substrate for cells to attach and proliferate, as well as
direct stem cell phenotype into the desired tissue type. In this study, we developed an
osteomimetic PLGA scaffold that allows for hESC attachment, proliferation, and
differentiation into osteogenic lineage. As previously mentioned, hESCs require surface
modification in order to be able to attach to 3D substrates. The ECM placed on the
scaffold can provide signals through proteins interacting with integrins, which in turn
influences cell phenotype. We hypothesized that native bone ECM deposited by human
osteoblasts (hOBs) will cover the surface of microsphere-sintered PLGA scaffolds, and
will direct the differentiation of hESCs into bone lineage by providing a natural bone
tissue microenvironment. This hypothesis is based on studies demonstrating the use of
native bone ECM components in stimulating hESCs and hMSCs to differentiate into
osteoblasts [98, 99]. To this end, the properties of the osteomimetic scaffolds such as
ECM composition and morphology as well as the in vitro differentiation of hESCs into
bone tissue were investigated.
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4.2 Synthesis of PLGA Microsphere-sintered Scaffolds
Scaffolds with diameters of 10 mm and heights of 2 mm were fabricated and used
in this study. Briefly, PLGA (75:25 lactide to glycolide ratio) (Lactel Absorbable
Polymers) was dissolved in dichloromethane (Sigma) to form a 1:4 w/v polymer solution.
This solution was added to a 1% poly(vinyl alcohol) solution (Sigma) while being stirred
at 330 rotations per minute (RPM) for 24 hours to allow for adequate evaporation of the
solvent. After harvesting the microspheres by vacuum filtration, the samples were
washed with deionized (DI) water and stored at -20°C for 24 hours. The microspheres
were lyophilized to completely remove all moisture. Commercially available micron
sieves were used to isolate microspheres of diameter 500-700 μm and they were placed
into stainless steel molds, heated at 85ºC for 12 hours, and sintered into cylindrical disks.

4.3 Human Osteoblast (hOB) Cell Culture and PLGA Scaffold Seeding
P3 human osteoblasts hFOB 1.19 (ATCC) were cultured in osteogenic
differentiation medium consisting of DMEM/F12 (Gibco), 10% FBS (Atlas), 10 mM βglycerophosphate (Sigma), 50 μg/mL ascorbic acid (Sigma), 1 μM dexamethasone
(Sigma), and 1% penicillin/streptomycin (Invitrogen). Medium was changed every other
day and cells were passaged once 80% confluency was reached. After two passages,
hOBs were trypsinized and seeded on the scaffolds.
Before seeding hOBs on the PLGA substrates, scaffolds were sterilized by
immersion in 70% ethanol for 10 minutes, washed 3x with phosphate buffered saline
(PBS), and exposed to UV light for 30 minutes on each side. hOBs were detached from
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the culture flask using trypsin and 20 μL (containing 5 x 105 cells) of cell suspension
were seeded per scaffold. Cells were cultured in osteogenic medium for 14 days and
culture medium was changed every other day.
Cell attachment and proliferation was analyzed during the 14 day culture period
using [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2Htetrazolium (MTS) (Promega) colorimetric assay. 300 μL of fresh media was added to
each scaffold, and incubated for 2 hours with 60 μL of MTS solution. The resulting
solution was diluted 1:5 and the absorbance was read at 492 nm using a UV Vis
Spectrophotometer.

4.4 Decellularization and Analysis
PLGA scaffolds were decellularized by adding a sterile solution of 0.25% Triton
X-100 (Sigma) and 0.25% deoxycholate (Alfa Aesar) dissolved in PBS for 30 minutes at
4°C, followed by incubation at 37°C for several hours. The decellularization solution was
removed and scaffolds were washed 3x with PBS.
Decellularized scaffolds were characterized by Alizarin Red S staining, calcium
quantification, alkaline phosphatase (ALP) staining, collagen II staining, and scanning
electron microscopy (SEM). To visualize the mineralized ECM, samples were first fixed
in 10% formalin for 30 minutes and washed 3x with DI water. Alizarin Red S staining
solution (pH 4.2-4.5) (Alfa Aesar) was added to the samples at a concentration of 0.02
mg/mL and incubated for 5 minutes. Samples were washed for 5 hours in 100% ethanol
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and ethanol was changed every 30 minutes. Mineralized ECM was visualized with a
Zeiss light microscope. To quantify the mineralized calcium, the O cresolphthalein
complexone (Sigma) method was used. DI water was used to wash the scaffolds 3x, and
0.6 mol/L hydrochloric acid was employed to homogenize the samples followed by 4
hours of shaking at 4 °C for calcium extraction. The amount of calcium was determined
by reading the absorbance at 570 nm with a UV Vis spectrophotometer. Alkaline
phosphatase was detected by using alkaline phosphatase kit #85 (Sigma) in which
scaffolds were fixed with 10% formalin for 30 minutes and washed 3x with PBS. The
Fast Blue capsule was dissolved in napthanol to prepare the staining solution, added to
the scaffold, and incubated for 30 minutes. The scaffolds were washed 3x with PBS
followed by incubation in the Mayer’s Hematoxylin solution for 10 minutes. ALP was
observed and photographed using a Nikon E600 light microscope. To determine collagen
II expression, scaffolds were fixed in 10% formalin for 30 minutes and washed 3x with
PBS. After washing, scaffolds were permeabilized using 0.1% Triton X-100 solution for
15 minutes. Cells were washed 3x with PBS and blocked using 1% bovine serum
albumin (BSA) (Sigma) in PBS for 30 minutes. FITC-conjugated anti-collagen II
antibody (1:100) (Thermo) was added to the scaffolds for 1 hour followed by washing 3x
with PBS. Cell nuclei were stained by adding 4’-6-diamidino-2-phenylindole (1:25)
(DAPI) (Sigma) antifade to the decellularized constructs. The samples were visualized
using a Zeiss 510 LSM confocal microscope and a water immersion lens. For SEM
analysis, cells on the scaffolds were fixed in 1% glutaraldehyde for 1 hour followed by
fixation in 3% glutaraldehyde at 4°C overnight. The scaffolds were dehydrated
sequentially by a series of increasing ethanol concentrations (10, 30, 50, 70, 90, 95, 95,
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100, 100%) for 15 minutes each. PGLA scaffolds were dried overnight and coated with
gold/palladium. Scaffolds were observed under Zeiss Ultra Plus FESEM after coating.

4.5 hESC Seeding
hESCs from cell line h9 (Wicell) p38 were grown on a feeder layer of mitomycin
C inactivated mouse embryonic fibroblasts (cell line PMEF-CFL) (Millipore) in medium
consisting of DMEM/F12 (Gibco), 20% Knock-out serum replacement (Gibco), 3.5 mM
L-Glutamine (Invitrogen), 100 μM β-mercaptoethanol (Sigma), 1% non-essential amino
acids (Invitrogen), and 10 ng/mL bFGF (Peprotech). The PMEF cell line was used as a
feeder layer and cultured in high glucose with L-glutamine DMEM (Gibco)
supplemented with 10% FBS and 1% penicillin/streptomycin (Invitrogen). Mitomycin C
(10 mg/mL) (Sigma) was used to inactivate PMEF cells for 2.5 hours, after which cells
were seeded at a density of 2.1 x 104 cells/cm2 on tissue culture plastic coated with 1%
gelatin (Sigma). Cells were cultured for 1 day in PMEF media prior to hESC seeding.
hESCs were detached from the tissue culture plate by a combination of the enzyme
collagenase IV (Sigma) and by manually scraping. Approximately 50,000 hESCs were
seeded per scaffold, and conditioned medium was used to ensure cell attachment
overnight. The following day, culture medium was changed from conditioned medium to
osteogenic differentiation medium. Osteogenic differentiation medium was changed the
following day to remove cell debris, then every 3 days for the remainder of the
experiment.
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For the control groups, two dimensional (2D) tissue culture polystyrene (TCPS)
and Geltrex-coated PLGA scaffolds were used. To coat the PLGA scaffolds and 2D
culture plates, 2.5 μL of Geltrex (Invitrogen) was mixed with 1 mL of cold DMEM/F12,
added to the scaffolds and plates, and incubated at 37°C for 1 hour, then incubated at
room temperature for 1 hour. Approximately 50,000 hESCs were seeded per well of a 24well plate, and per Geltrex-coated PLGA scaffold.

4.6 Cell Attachment, Growth, and Morphology
At predetermined time points, cell morphology was assessed using SEM. Cells on
the scaffolds were prepared as previously described and observed under a Zeiss Ultra
Plus FESEM after coating.
Cell proliferation on scaffolds was assessed using [3-(4,5-dimethylthiazol-2-yl)-5(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium

(MTS)

(Promega)

colorimetric assay. 300 μL of fresh media was added to each scaffold, and incubated for 2
hours with 60 μL of MTS solution. The resulting solution was diluted 1:5 and the
absorbance was read at 492 nm using a UV Vis Spectrophotometer.
Cytoskeleton formation was observed by F-actin staining. Cells on the scaffolds
were fixed at room temperature in 10% formalin for 30 minutes. After washing scaffolds
3x with PBS, cells were permeabilized using a 0.1% Triton X-100 solution for 15
minutes. Cells were then washed 3x with PBS and blocked using 4% Goat Serum in PBS
for 30 minutes. TRITC-conjugated phalloidin (1:40) (Invitrogen) was added to the
scaffolds for 1 hour, samples were washed 3x with PBS, and cell nuclei were stained with
40

4’-6-diamidino-2-phenylindole (1:25) (DAPI) (Sigma). Stained cells were visualized
using a Zeiss 510 LSM confocal microscope under a water immersion lens.

4.7 Assessment of Osteogenic Differentiation
Osteogenic differentiation was assessed by monitoring the calcium deposition,
osteocalcin expression, and qRT-PCR analysis of RUNX2 and BGLAP genes.
Calcium was quantified using the O cresolphthalein complexone (Sigma) method. At
predetermined time points, cell culture medium was removed from the scaffolds and cells
were washed 3x with DI water. 0.6 mol/L hydrochloric acid was used to homogenize the
samples followed by 4 hours of shaking at 4 °C for calcium extraction. Samples were
compared against CaCl2 standards and the amount of calcium was determined by reading
the absorbance at 570 nm with a UV Vis spectrophotometer.
ECM mineralization was assessed using Alizarin Red S staining. Samples were fixed
in 10% formalin for 30 minutes and washed 3x with DI water. Alizarin Red S staining
solution
(pH 4.2-4.5) (Alfa Aesar) was added to the samples at a concentration of 0.02 mg/mL and
incubated for 5 minutes. Samples were washed for 5 hours in 100% ethanol, and ethanol
was changed every 30 minutes. Mineralized ECM was visualized with a Nikon E600
light microscope.
Osteocalcin was qualitatively observed by immunofluorescence staining. In brief,
cells were fixed in 10% formalin for 30 minutes, followed by washing 2x with a rinse
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buffer (20 mM Tris-HCL and 0.05% Tween- 20 in PBS) (Sigma). The sample was then
permeabilized with 0.1% Triton X-100 (Sigma) in PBS for 15 minutes, and washed 2x
with the rinse buffer. Cells were blocked with 4% goat serum in PBS for 30 minutes. The
primary antibody, osteocalcin (1:50) (R&D Systems), was added to the scaffolds and
incubated for 60 minutes. Following the primary antibody incubation, the samples were
washed 3x with the rinse buffer for 5 minutes each time. Then Alexafluor 594 (1:1000)
(Invitrogen) was added to the samples and incubated for 1 hour, followed by 4’-6diamidino-2-phenylindole (1:25) (DAPI) (Sigma) nuclear stain. Stained cells were
visualized using a Zeiss 510 LSM confocal microscope under a water immersion lens.
Total RNA was extracted from the samples using the GeneJET RNA Purification Kit
(Thermo Scientific). One μg of RNA was used as a template for single-strand cDNA
synthesis with the RevertAid First Strand cDNA Synthesis Kit (Thermo Scientific). In
brief, RNA was prepared by first removing genomic DNA from the sample. The reaction
buffer with MgCl2, DNase I, and nuclease-free water was added to 1 μg of RNA to a total
volume of 10 μL. The sample was incubated at 37 °C for 30 minutes, then 1 μL 50 mM
EDTA was added and incubated at 65 °C for 10 minutes. The template RNA was mixed
with 1 μL oligo (dT)18 primer and nuclease-free water to a volume of 12 μL, followed by
the addition of 4 μL of 5x Reaction Buffer, 1 μL Ribolock RNase Inhibitor, 2 μL 10 mM
dNTP Mix, and 1 μL RevertAid M-MuLV Reverse Transcriptase. This mixture was then
incubated at 42 °C for 1 hour. The SensiFAST SYBR No-ROX Kit (Bioline) was used
for qPCR. 100 ng of cDNA was mixed with 10 μL 2x SensiFAST SYBR No-ROX Mix,
10 μM forward primer, 10 μM reverse primer, (see Table 1 for sequences) and nuclease-
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free water to 20 μL. A 3-step cycling was used on a Bio-Rad CFX96 instrument: 1 cycle
of 95 °C for 2 minutes to activate the polymerase, followed by 40 cycles of 95 °C for 5s
to denature, 65 °C for 10s for annealing, then 10s at 72 °C for extension.

Gene

expression of RUNX2 and BGLAP were normalized to GAPDH and presented as relative
values.

4.8 Statistical Analysis
Three samples (n=3) were analyzed per condition unless otherwise stated. Error bars in
graphs represent mean ± standard deviation (SD). One-way analysis of variance (one-way
ANOVA) was used to determine statistical significance. Comparison between the two
means was determined by the Tukey test and statistical significance was defined as p ≤
0.05.

4.9 Results
Figure 4.1 demonstrates the growth of hOBs on PLGA scaffolds during the 14 day
culture period. The number of cells was determined for days 1, 4, 7, and 14. Cells
attached to the scaffolds and cell number steadily increased at each sequential time point.
From this assay it was confirmed that cells were proliferating, therefore depositing ECM
on the substrate.
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Table 4.1 Primer sequences used in qRT-PCR to analyze osteogenic differentiation of
hESCs on osteomimetic PLGA.
Primer Name

Sequence

RUNX2 Forward

5’-CTC ACT ACC ACA CCT ACC TG-3’

RUNX2 Reverse

5’-TCA ATA TGG TCG CCA AAC AGA TTC-3’

BGLAP Forward

5’-GGC GCT ACC TGT ATC AAT GG-3’

BGLAP Reverse

5’-TCA GCC AAC TCG TCA CAG TC-3’
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Figure 4.2 shows characterization of the microsphere-sintered PLGA scaffolds. The
scaffolds were all highly porous with interconnected structures, and demonstrated similar
architecture to that of trabecular bone. SEM images of decellularized scaffolds (Figure
4.2A) showed ECM deposition covering the surface of the microspheres, with collagen
fibrils clearly defined. Alizarin Red S staining indicated the presence of calcium in the
mineralized ECM (Figure 4.2B), while collagen II staining demonstrated the presence of
collagen II in the ECM (Figure 4.2C). The enzyme ALP was also found on the surface of
the decellularized PLGA scaffolds, as shown by the purple/blue stain indicative of ALP
(Figure 4.2D). The quantification of the mineralized calcium on the decellularized
scaffolds indicated that an average of 1.17 μg of calcium was present per construct.
Figure 4.3 demonstrates cell attachment and morphology of hESCs (Figure 4.3A),
and proliferation and morphology of hESC-derived osteogenic progenitors (Figure 4.3B).
The hESC colonies were able to attach to the decellularized matrix, initially in large,
compact colonies (Figure 4.3A). They continued to grow and spread, and after 7 days the
cells no longer exhibited an undifferentiated hESC phenotype (Figure 4.3B). The cells
formed bridges between microspheres and fully covered the scaffold surface at day 35
(Figures 4.3C and 4.3D). Cell proliferation was monitored by the MTS assay, and in all
conditions, cells increased in number (Figure 4.4). Interestingly, the decellularized
scaffold group had the highest cell numbers compared to the Geltrex-coated PLGA
group, with the exception of day 7. Cytoskeleton organization and morphology was
observed by SEM and immunofluorescence staining of F-actin and DAPI (Figure 4.5A
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Figure 4.1 Proliferation of hOBs on PLGA scaffolds at time points of day 1, day 4,
day 7, and day 14. Cell number steadily increased during the 14 day culture period.
# represents a significant difference in cell number between day 14 and day 1 at a
significance level of p<0.2.
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Figure 4.2 Analysis of osteomimetic scaffolds. (A) SEM image of ECM covering
surface of PLGA scaffold, scale bar 10 μm and magnification 2000x; (B) Alizarin
Red S staining of calcium depostited by hOBs on scaffold surface, scale bar 200 μm
and magnification 10x; (C) Collagen II staining of ECM confirms ECM composition,
scale bar 50 μm and magnification 20x; (D) ALP staining of ECM covering surface of
PLGA scaffold, scale bar 500 μm and magnification 4x.
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and 4.5B, respectively). We observed that the cells proliferated on the surface of the
scaffolds and within the pores, and there was no noticeable variation in cytoskeleton
structure and morphology among the groups.
Osteogenic differentiation was assessed by observing calcium content, osteocalcin
expression, and qRT-PCR to quantify osteogenic marker genes. The highest level of
calcium content was expressed by the hESCs on the decellularized scaffolds, followed by
the Geltrex-coated PLGA group, with the 2D TCPS group demonstrating the least
amount of mineralized matrix (Figure 4.6A). The immunofluorescence staining of the
differentiated cells on the scaffolds showed that osteocalcin was present in the
differentiated hESCs on the decellularized scaffolds, Geltrex-coated PLGA scaffolds, and
2D TCPS. The highest level of osteocalcin was detected in the decellularized scaffold, as
shown in figure 4.5C. In order to quantitatively evaluate the marker genes indicative of
osteogenic differentiation, qRT-PCR was employed. It was found that the decellularized
scaffolds as well as the PLGA scaffolds exhibited the highest expression of RUNX2 as
compared to the 2D culture plate (Figure 4.6B). BGLAP levels were the highest in
decellularized scaffolds, followed by the PLGA scaffolds and 2D TCPS (Figure 4.6C).
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Figure 4.3 SEM images of hESCs and hESC-derived osteogenic progenitors on
osteomimetic scaffolds. (A) Day 0 shows colony attachment, indicated by white
arrow, scale bar 100 μm and magnification 300x; (B) Day 7 demonstrates the onset of
differentiation, scale bar 10 μm and magnification 500x; (C) Day 35 shows
differentiated cells with osteoblast-like morphology, scale bar 100 μm and
magnification 100x; (D) Day 35 differentiated hESCs, scale bar 20 μm and
magnification 200x.
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Figure 4.4 Proliferation of hESCs on Geltrex-coated PLGA and osteomimetic
scaffolds, shown as cell number/scaffold. * and + represent significant difference in
cell number between the Geltrex-coated PLGA and the osteomimetic scaffolds at
significance levels of p<0.05 and 0.1, respectively.
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Figure 4.5 Confocal images of day 35 differentiated hESCs on osteomimetic
PLGA, scale bars 50 μm and magnification 20x. (A) Actin demonstrates
cytoskeleton formation; (B) DAPI shows nuclear staining; (C) Osteocalcin
expression; and (D) a merged image of actin, DAPI, and osteocalcin.
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Figure 4.6 Calcium deposition and gene expression of differentiated hESCs on 2D
culture plates, Geltrex-coated PLGA, and osteomimetic PLGA. *, +, and ^
represents significant difference in calcium content and gene expression by cells
on osteomimetic scaffolds compared to Geltrex-coated PLGA and 2D tissue
culture plates at significance levels of p<0.05, 0.1, and 0.5, respectively. (A)
Calcium quantification for each group represented as μg/substrate where the
substrate is the scaffold for the osteomimetic PLGA and geltrex-coated PLGA
groups, and the 2D well surface for the TCPS group; (B) Relative RUNX2 gene
expression (n=2); (C) Relative BGLAP gene expression (n=2). All values were
normalized to GAPDH.
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4.10 Discussion
The ability to develop a 3D porous scaffold with comparable mechanical and
structural properties to that of natural bone governs the success of many bone tissue
engineering endeavors. Bone is a complex tissue composed of an architectural hierarchy:
(i) the macrostructure which is made up of cortical and cancellous bone, (ii) the
microstructure which is composed of osteons, haversian systems, and trabeculae, (iii) the
submicrostructure which is comprised of the lamellae, (iv) the nanostructure which is
predominately composed of collagen I fibers, and (v) the sub-nanostructure made up of
mineralized matrix, smaller collagen subunits, and other organic proteins [15]. Due to
this intricate tissue configuration, recreating bone structure is a major hurdle in
generating scaffolds. Another obstacle in bone tissue engineering studies is deciphering
specific roles of scaffold design parameters governing in vitro osteogenic differentiation
and in vivo osteointegration.
The research work described in this study centers in on designing an osteomimetic
scaffold composed of microsphere-sintered PLGA scaffolds and native bone ECM
components secreted by osteoblast cells. These scaffolds were then applied to an in vitro
study that analyzed the osteogenic differentiation of hESCs seeded on these
decellularized scaffolds as compared to the control Geltrex-coated PLGA scaffolds and
2D tissue culture polystyrene group. It was hypothesized that hESCs seeded on the native
bone ECM scaffolds would exhibit faster osteogenic differentiation as well as greater
expression of mineralized matrix, higher levels of osteocalcin expression, and greater

53

levels of bone marker genes such as RUNX2 and osteocalcin. A rationale for this work
was based off of recent studies that demonstrated the potential of decellularized bone
matrices in directing the differentiation of hESCs and hMSCs into osteogenic lineage [98,
99].
In this study, we used microsphere-sintering to develop scaffolds. This fabrication
technique produces scaffolds of tunable porosity and mechanical strength within the
range of trabecular bone [276, 283]. Osteoblasts readily attach to PLGA substrates
through proteins in the FBS adsorbing to the surface of scaffolds allowing for integrinligand interactions, however hESCs need surface modifications in order to adhere to the
scaffolds. To alter the surface of the substrate for promoting the attachment of hESCs, a
native bone microenvironment was generated by seeding hOBs on the PLGA scaffolds,
then removing the cells while leaving the ECM intact. During the 14 day culture period,
hOBs proliferated on the scaffolds and deposited ECM on the surface of the substrate.
The ECM secreted by the osteoblasts contained calcium, alkaline phosphatase, collagen
II, and other proteins found in bone structure. Since bone is formed via endochondral
ossification in the embryo, the collagen II structure laid down by the hOBs is thought to
stimulate the natural signaling pathways for hESCs to differentiate into osteogenic
lineage [284].
Cell attachment and morphology was assessed by using SEM. Cell shape is indicative
of adhesion since cells that have a spread-out morphology have more focal adhesions and
greater cell-substrate contact than cells exhibiting a round morphology. Differentiated
hESCs on the Geltrex-coated PLGA scaffold and decellularized PLGA scaffold
demonstrated a spread phenotype, and the cells were able to migrate throughout the
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scaffold by forming extensions between adjacent microspheres. This result is consistent
with previous studies demonstrating the proliferation of primary fibroblasts and
osteoblasts on PLGA microsphere-sintered scaffolds [276, 283, 285].
In line with other studies, our in vitro evaluation of the decellularized scaffolds
demonstrated a higher level of osteogenic differentiation as compared to the control
groups. hESCs underwent differentiation over a 35 day period as a result of physical cues
from the native ECM scaffolds and chemical growth factors in the differentiation media.
The extent of differentiation was measured by quantifying calcium expression, as well as
immunofluorescence staining of osteocalcin and by analyzing gene expression of
osteocalcin and RUNX2 by qRT-PCR. Common methods of analyzing osteogenic
differentiation include quantifying alkaline phosphatase, collagen I, non-collagenous
proteins such as osteocalcin, and the existence of bone apatite [286]; however these
qualities are not unique to bone-forming osteoblasts. The most stand-alone method of
determining osteoblast differentiation besides analyzing mRNA is the observation of a
cell-mediated calcified extracellular matrix [287]. We determined calcium content of
each experimental group, and the osteomimetic scaffolds expressed the highest amount as
compared to the 2D control and Geltrex-coated PLGA scaffolds. Our study showed that
3D microenvironments produced from microsphere-sintered PLGA scaffolds generates a
higher level of hESC differentiation into osteogenic lineage as compared to cells grown
on 2D tissue culture plates. Furthermore, our results from these tests demonstrate that the
presence of native bone ECM on 3D PLGA scaffolds leads to an elevated expression of
osteogenic markers. RUNX2 is the main transcription factor for the osteoblast, and it is
exclusively required for osteoblast differentiation [97]. RUNX2 expression determines
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osteogenic lineage commitment, therefore the upregulation of RUNX2 mRNA quantified
by qRT-PCR demonstrates the differentiation of hESCs into osteoblasts.
The advantage of our synthetic scaffolds coated with bone ECM is that we can design
the polymer to mimic the structure of trabecular bone while exhibiting similar mechanical
properties. This eliminates the risk of immunogenicity associated with using bone from
humans or animals that has been decellularized. Decellularized scaffolds offer a native
bone microenvironment in which stem cells can receive signals from the proteins and
embedded growth factors. These signals govern cell type and function.
The enthusiasm for using hESCs as a source for bone tissue is hindered by ethical
concerns as well as the need to establish protocols to obtain a homogenous population of
differentiated cells [83, 288]. Also, the risk of teratoma formation is a major issue in
using hESCs in vivo [289, 290]. Future directions of this study include delineating the
mechanisms by which native bone ECM components and architecture modulates the
osteogenic differentiation of hESCs. This will enable us to design a scaffold that induces
cells to exclusively form components of bone and it will ensure that teratoma formation
will not occur.

4.11 Conclusions
In this study, osteomimetic PLGA scaffolds were fabricated by microsphere-sintering
and by utilizing hOBs to deposit bone ECM on the surface of the polymer. The native
bone ECM substrates resembled bone tissue in composition. The potential of these
scaffolds as bone graft substitutes was evaluated by the in vitro differentiation of hESCs
on the osteomimetic substrates as well as Geltrex-coated PLGA and 2D tissue culture
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plates. Our results demonstrated that the decellularized scaffolds promoted cell adhesion,
proliferation, and osteogenic differentiation. Incorporating native components of boneECM with PLGA scaffolds has proven to be a successful approach to tissue engineering
bone. A more detailed study is warranted to parse the in vivo mechanisms by which ECM
proteins regulate osteogenesis.
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CHAPTER 5: RESVERATROL AS A STIMULATOR OF OSTEOGENESIS AND
MODULATOR OF INFLAMMATION
5.1: Introduction
Tissue engineering offers a revolutionary approach to restore bone tissue and heal
critical-size defects resulting from trauma, infection, tumor resection or other
musculoskeletal diseases [1]. This is traditionally accomplished by utilizing a
combination of biomaterials, cells, and signaling factors. Biomaterials provide a threedimensional substrate with specific engineered characteristics for cells to attach and
proliferate. Growth factors supply essential signaling cues for cells to migrate and
differentiate into the desired tissue type. Cells seeded on 3D biomaterials contribute to
the healing process through signaling events that guide newly formed tissue integration
with the host tissue.
The success of tissue engineering strategies is contingent on the ability of blood
vessels to form within the scaffolds and supply nutrients to the transplanted cells [291].
This process is controlled through a cascade of events that are mediated by chemotaxis
and the host inflammatory response. Inflammation is the process by which the body
protects itself from intruders, and if left uncontrolled, potentially interferes with the
integration of implanted biomaterials. The complicated interplay of immune cells and
signaling molecules at the interface of an implanted engineered graft must be parsed in
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order to effectively design a method to harness host inflammation to promote wound
healing.
As mentioned in Chapter 1, Section 3, the body responds to an implanted
biomaterial with a critical sequence of the host immune reactions. The host inflammatory
response is commonly initiated when native vasculature is disrupted, and the release of
serum proteins from the vasculature adsorb to the implanted biomaterial surface. This
forms the provisional matrix composed of fibrin, platelet granule components such as
thrombospondin, TGF-α, TGF-β, PDGF, PF4, and ECGF1 [28]. Monocytes exit the
capillaries, differentiate into pro-inflammatory M1 macrophages, and attach to the
provisional matrix. The secretion of cytokines such as TNF-α, IL-1β, IL-6, and MCP-1
drives the acute inflammation response [29, 30]. Following the acute inflammatory
response, chronic inflammation manifests at the biomaterial-host interface. This is
defined by the presence of macrophages, monocytes, lymphocytes, blood vessel
proliferation, and connective tissue formation [31-34]. Foreign body giant cells and
macrophages will exist at tissue-implant interface for the duration of the biomaterial’s
lifetime [35-39]. A fibrous capsule forms as a result, separating the biomaterial from the
host tissue [28]. In some tissue types, acute inflammation stimulates M1 proinflammatory macrophages to change phenotype into wound healing M2 macrophages.
The polarization of M1 to M2 is a critical component of attenuating graft and biomaterial
rejection.
Several strategies have been designed to mediate the host inflammation in
response to biomaterials. In one approach, a hydrophilic boundary between implant and
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host tissue [40, 41] was created to enhance the biocompatibility of implants [42-44]. In
another approach, anti-inflammatory biomolecules were utilized to inhibit the secretion
of mediators such as leukotrienes and prostaglandins, and delay fibroblast capsule
formation [52]. A major drawback of this method is the numerous undesired systemic
side effects [53]. For example, anti-inflammatory corticosteroid based drugs inhibit new
blood vessel formation necessary for nutrient exchange in the implanted tissue [54, 55].
Another commonly used method is the induction of angiogenesis based on the use of
growth factors [46-48]. Despite its limited success, this method can overexpose tissues to
growth factors leading to arthritis and tumor formation [49-51].
Efforts to identify compounds with anti-inflammation properties have led to
discovery of resveratrol, a polyphenol found in the skin of grapes [292, 293]. Strikingly,
this molecule has been shown to exhibit therapeutic effects in a number of diseases
including cancer, cardiovascular failure, viral infections, neurodegeneration, and
ischemic injuries [294-304]. The exact mechanisms by which resveratrol impacts
inflammation is under intense investigation. Suppression of transcription factor nuclear
factor kappa B (NF-κB), TNF-α and interleukin-1 (IL-1), prostaglandin E2 (PGE2), and
nitric oxide (NO) synthesis have demonstrated to be potential means by which resveratrol
attenuates inflammation [305-307]. Further studies are warranted to explore the signaling
cascades governing the anti-inflammatory potential of resveratrol in the context of wound
healing and implant integration.
In addition to its anti-inflammatory characteristic, resveratrol has been found to
possess pro-osteogenic properties. Augmentation of the canonical Wnt signaling
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pathway, activation of sirtuin 1 (SIRT-1), and acetylation of runt-related transcription
factor 2 (RUNX2) have been shown to be the underlying mechanism behind the
induction of osteogenesis in stem cells by resveratrol [308-311]. Additionally, reports of
the bone inductive effects of resveratrol through the activation of estrogen receptor have
highlighted this natural compound as a viable candidate factor for bone tissue engineering
applications.
The main objective of this study is to determine the potential of resveratrol to
lessen inflammation and stimulate hMSCs towards bone lineage in 2D culture systems.
The hypothesis behind our effort is that resveratrol can be utilized to (i) induce the
osteogenic differentiation of hMSCs, and (ii) switch macrophage polarization from a proinflammatory M1 to a wound healing M2 phenotype. We tried this hypothesis by
assessing the time-dependent effect of varying resveratrol doses on macrophage gene
expression as well as hMSCs osteogenic differentiation in 2D culture systems. The
approach developed in this study has the potential to be applied to 3D scaffold design for
harnessing inflammation and promoting bone tissue formation.

5.2: Human Monocyte Cell Culture
Human THP-1 monocytes (sigma) were cultured in basal medium consisting of
RPMI 1640 (Sigma), 2 mM L-Glutamine (Gibco), 10% FBS (Atlas), and 1%
penicillin/streptomycin (Invitrogen). Medium was changed every other day, and cells
were kept at a density of 3-8 x 106 cells/mL in order to maintain growth. THP-1
monocytes were seeded in each well of a 24 well plate at a number of 500,000 cells per
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well. Depending on the experimental conditions, cells were kept at an undifferentiated
state, were differentiated to M0 macrophages, or were differentiated to M1 macrophages.

5.3: Differentiation of Monocytes to Macrophages
THP-1 monocytes were differentiated to M0 macrophages by adding 200 nM
phorbol 12-myristate 13-acetate (PMA) to the basal medium for 24 hours after which
cells adhered to the tissue culture plate. To differentiate M0 macrophages to M1
macrophages, basal medium supplemented with 1 μg/mL LPS (Sigma) and 20 ng/mL
recombinant interferon gamma (IFNγ) (Peprotech) was added to the wells for 24 hours.
Differentiation of M0 macrophages to M2 macrophages was accomplished by adding 20
ng/mL recombinant interleukin 4 (IL-4) (Peprotech) as well as 20 ng/mL recombinant
interleukin-13 (IL-13) (Peprotech) to the basal medium, and then culturing M0
macrophages in the differentiation medium for 18 hours.

5.4: Effect of Resveratrol on M1 Macrophages
Resveratrol was added to basal THP-1 monocytes culture medium at concentrations
of 1 μM, 10 μM, and 25 μM, and gene expression of cytokines VEGF, TNF-α, IL-6,
macrophage mannose receptor 1 (MRC-1), and interleukin 10 (IL-10) were analyzed
using qRT-PCR after resveratrol exposure durations of 2 and 5 days.
The total RNA was extracted and purified from the samples using the GeneJET RNA
Purification Kit (Thermo Scientific). Briefly, RNA (0.5 μg) was prepared as a template
for single-strand cDNA synthesis using the RevertAid First Strand cDNA Synthesis Kit
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(Thermo Scientific). First, genomic DNA was removed from the RNA sample by
applying a mixture of the supplied reaction buffer with MgCl2, DNase I, and nucleasefree water to a total volume of 10 μL. The samples were then incubated at 37 °C for 30
minutes, after which 1 μL 50 mM EDTA was added. The samples were placed in a 65 °C
water bath for 10 minutes. The template RNA was mixed with 1 μL oligo (dT)18 primer
and nuclease-free water to a volume of 12 μL, followed by the addition of 4 μL of 5x
Reaction Buffer, 1 μL Ribolock RNase Inhibitor, 2 μL 10 mM dNTP Mix, and 1 μL
RevertAid M-MuLV Reverse Transcriptase. This mixture was incubated at 42 °C for 1
hour in a Bio-Rad CFX96 thermocycler instrument. To detect gene expression, the
SensiFAST SYBR No-ROX Kit (Bioline) was used for qPCR. Briefly, 100 ng of cDNA
was mixed with 10 μL 2x SensiFAST SYBR No-ROX Mix, 10 μM forward primer, 10
μM reverse primer, (see Table 5.1 for primer sequences, Integrated DNA Technologies)
and nuclease-free water to 20 μL. A 3-step cycling was used on a Bio-Rad CFX96
instrument: 1 cycle of 95 °C for 2 minutes to activate the polymerase, followed by 40
cycles of 95 °C for 5s to denature, 65 °C for 10s for annealing, and 10s at 72 °C for
extension. Gene expression of VEGF, TNF-α, IL-6 MRC-1, and IL-10 were normalized
to GAPDH and presented as relative values.

5.5: Human Mesenchymal Stem Cell Culture and Osteogenic Differentiation with
Resveratrol
Human mesenchymal stem cells were cultured in a basal medium consisting of
DMEM/F12 (Gibco), 10% FBS (Atlas), and 1% penicillin/streptomycin (Invitrogen).
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Table 5.1. Primers used for quantitative real-time polymerase chain reaction to
demonstrate macrophage phenotype and hMSC differentiation.

Gene
VEGF-A
IL-10
TNF-α
MRC-1
IL-6
BGLAP
RUNX2
GAPDH

5’-3’ primer sequences: (F: forward R: reverse)
F: ATC TGC ATG GTG ATG TTG GA
R: GGG CAG AAT CAT CAC GAA GT
F: GTG ATG CCC CAA GCT GAG A
R: CAC GGC CTT GCT CTT GTT TT
F: CTG CTG CAC TTT GGA GTG AT
R: AGA TGA TCT GAC TGC CTG GG
F: CAG CGC TTG TGA TCT TCA TT
R: TAC CCC TGC TCC TGG TTT TT
F:AGC CAC TCA CCT CTT CAG AAC
R: GCC TCT TTG CTG CTT TCA CAC
F: GGC GCT ACC TGT ATC AAT GG
R: TCA GCC AAC TCG TCA CAG TC
F: CTC ACT ACC ACA CCT ACC TG
R: TCA ATA TGG TCG CCA AAC AGA TTC
F: GTG GAC CTG ACC TGC CGT CT
R: GGA GGA GTG GGT GTC GCT GT

64

Medium was changed every 5 days and cells were passaged once 80% confluency was
reached.
To study the impact of resveratrol on osteogenic differentiation, hMSCs were
seeded in a 24 well plate (50,000 cells/well) for 24 h after which the culture medium was
changed. Four conditions were considered in this study: basal medium (negative control),
basal medium supplemented with 12.5 μM resveratrol (Sigma), osteogenic medium, or
osteogenic medium supplemented with 12.5 μM resveratrol. Growth media was
exchanged 3 times per week for all groups.

5.6: Analysis of hMSC Proliferation and Osteogenic Differentiation
Samples

were

characterized

by

MTS

proliferation

assay,

osteocalcin

immunofluorescence staining, Alizarin Red S staining, calcium quantification, alkaline
phosphatase (ALP) staining, and ALP quantification.
Cell proliferation was monitored using [3-(4,5-dimethylthiazol-2-yl)-5-(3carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium

(MTS)

(Promega)

colorimetric assay. Fresh media was added to each well at a volume of 100 μL, and
incubated for 4 hours with 20 μL of MTS solution. The resulting solution was diluted 1:5
and the absorbance was read at 492 nm using a Biotek Synergy 2 plate reader.
Osteocalcin was qualitatively assessed using immunofluorescence staining. Cells
were fixed in 10% formalin for 30 minutes, followed by washing with a rinse buffer (2x)
(20 mM Tris-HCL and 0.05% Tween- 20 in PBS) (Sigma). The samples were

65

permeabilized with 0.1% Triton X-100 (Sigma) in PBS for 15 minutes. Cells were
washed 2x with the rinse buffer, and blocked with 4% goat serum in PBS for 30 minutes.
The primary antibody, osteocalcin (1:50) (R&D Systems), was added to the samples and
incubated overnight at 4°C. Following the primary antibody incubation, the cells were
washed 3x with the rinse buffer for 5 minutes each time. Then Alexafluor 594 (1:1000)
(Invitrogen) was added to the samples and incubated for 1 hour at room temperature,
followed by 4’-6-diamidino-2-phenylindole (1:25) (DAPI) (Sigma) nuclear stain. Images
of stained cells were obtained using a Nikon Eclipse 80i with NIS-Elements imaging
software.
To visualize the mineralized calcium, samples were fixed in 10% formalin for 30
minutes and washed 3x with DI water. Alizarin Red S staining solution (pH 4.2-4.5)
(Alfa Aesar) was added to the samples at a concentration of 0.02 mg/mL and incubated
for 5 minutes. Samples were washed for 6 hours in 100% ethanol as ethanol wash
solution was changed every 30 minutes. Mineralized ECM was imaged with a Nikon
E600 light microscope. To quantify the mineralized calcium, the O cresolphthalein
complexone (Sigma kit #MAK022) method was employed. The scaffolds were washed
with deionized (DI) water 3x followed by the use of 0.6 mol/L hydrochloric acid to
homogenize the samples and 4 hours of shaking at 4°C for total calcium extraction. Each
sample was added to individual wells of a 96 well plate at a volume of 50 μL, and 90 μL
of the supplied chromogenic reagent was placed in each well containing the samples.
After mixing gently, a total of 60 μL of calcium assay buffer was added to each well and
carefully merged with the other components. The reaction was incubated for 10 minutes
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in the dark, and the amount of calcium was determined by reading the absorbance at 575
nm with a Biotek Synergy 2 plate reader.
ALP expression was quantified using a Bio-Rad Alkaline Phosphatase Substrate
Kit (#172-1063). Briefly, cells were washed 3x with PBS, then lysed using 0.1% Triton
X-100 (Sigma) in PBS for 15 minutes at 4 °C. The substrate solution was reconstituted
by mixing 1 mL of 5x diethanolamine buffer with 4 mL DI water, then dissolving 1 tablet
of 5 mg p-nitrophenylphosphate in the buffer mixture. Each sample was placed in
individual wells of a 12 well plate at a volume of 400 μL. A total of 100 μL substrate
solution was added to the samples and incubated at 37 °C for 30 minutes in the dark after
which 100 μL 0.4 M NaOH to stop the reaction. The absorbance was read at 405 nm
using a Biotek Synergy 2 plate reader. ALP was quantitatively detected by using alkaline
phosphatase kit #85 (Sigma) in which scaffolds were fixed with 10% formalin for 30
minutes and washed 3x with PBS. The Fast Blue capsule was dissolved in napthanol to
prepare the staining solution, added to the scaffold, and incubated for 30 minutes. The
scaffolds were washed 3x with PBS followed by incubation in the Mayer’s Hematoxylin
solution for 10 minutes. ALP was observed and imaged using a Nikon E600 light
microscope.

5.7: Resveratrol Modulates Inflammation by Inducing Macrophage Phenotypic Switch
Figure 5.1 shows the dose dependent effects of resveratrol on M1 macrophages.
Analysis of inflammatory gene (IL-6, TNF-α) and anti-inflammatory gene (VEGF, MRC1 and IL-10) expression by qRT-PCR demonstrated that resveratrol modulates
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inflammation and promotes anti-inflammatory cytokine expression. Inflammatory marker
IL-6 was significantly lowered with the addition of 10 μM and 25 μM resveratrol at day
2, and reduced equally by all concentrations of resveratrol by day 5 (Figure 5.1A).
Consistently, TNF-α was greatly reduced at the 2 day time point by 25 μM of resveratrol.
Day 5 showed a dose dependent trend of lowered TNF-α expression, with a statistically
significant reduced inflammatory cytokine level expressed in the 25 μM resveratrol
containing group (Figure 5.1B). The expression of anti-inflammatory marker IL-10
significantly increased at the 2 day and 5 day time points with the addition of 25 μM
resveratrol (Figure 5.1C). Similarly, VEGF expression increased with the addition of
resveratrol, and day 2 expression showed statistically significant levels in the 1 μM group
as compared to the control (Figure 5.1D). By day 5, VEGF levels were the greatest with
M1 macrophages cultured with 25 μM, followed by 10 μM and 1 μM. In line with these
results, MRC-1 levels were statistically significant for the M1 macrophages cultured with
25 μM resveratrol at both time points, as compared to the control group (Figure 5.1E).

5.8: Resveratrol Drives the Osteogenic Differentiation of hMSCs
Figure 5.2 demonstrates the effect of resveratrol on the osteogenic stimulation of
hMSCs. Cells were cultured in basal hMSC medium, basal medium supplemented with
resveratrol, osteogenic differentiation medium, and osteogenic differentiation medium
supplemented with resveratrol. Differentiation was analyzed over a period of 21 days. It
is important to note that in all of the 2D study, hMSCs exhibited a normal proliferation
curve with no significant difference in cell growth between the study groups.
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Osteogenesis was assessed based on calcium, ALP, and OCN expression.
Calcium expression was analyzed at days 7, 14, and 21 (Figure 5.2A). At each time point,
cells cultured in osteogenic medium supplemented with resveratrol produced
significantly higher amounts of calcium as compared to all other groups. Cells in basal
medium with resveratrol as well as hMSCs cultured in osteogenic medium demonstrated
a statistically higher level of calcium at days 14, and 21, as compared to the control.
Calcium expression for hMSCs cultured in osteogenic medium with resveratrol is further
demonstrated by Alizarin Red S Staining (Figure 5.2B) which shows a bright red color
indicating mineralized matrix.
Alkaline Phosphatase expression was determined at time points of 7, 14, and 21
days. Cells cultured in osteogenic medium supplemented with resveratrol exhibited a
statistically higher amount of ALP at every time point as compared to all other groups
(Figure 5.2C). Cells cultured in basal medium with resveratrol as well as osteogenic
medium showed significant ALP expression at day 21. ALP staining confirmed the
expression at day 21 of culture in osteogenic medium with resveratrol, as shown by the
bright purple-blue color of the cells (Figure 5.2D).
Gene expression analysis of OCN demonstrated a significant higher level of gene
expression in the basal medium supplemented with resveratrol at day 7 (Figure 5.2E). At
days 14 and 21, cells cultured with resveratrol in osteogenic medium expressed
statistically higher OCN, as compared to the control. Osteocalcin immunofluroescent
staining further confirmed OCN level at day 21 expressed by hMSCs cultured in 12.5 μM
resveratrol (Figure 5.2F).

69

Figure 5.1 Gene expression by M1 macrophages cultured under different resveratrol
concentration was analyzed by measuring the levels of (A) IL-6, (B) TNF-α, (C) IL-10,
(D) VEGF, and (E) MRC-1using qRT-PCR. A single asterisk denotes significantly
higher as compared to groups denoted by two asterisks. Two single asterisk denotes
significantly higher as compared to groups denoted by three asterisks. Results
demonstrated the highest level M2 signatory genes in the presence of resveratrol
demonstrating the potential to drive the pro-angiogenic and anti-inflammatory response.
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Figure 5.2 (A) Calcium expression was the greatest for hMSCs cultured in osteogenic medium +
resveratrol. (B) Alizarin Red S staining confirmed calcium deposition by hMSCs cultured in
osteogenic medium + resveratrol at day 21, scale bar is100 μm. (C) ALP expression was the
highest for hMSCs in osteogenic medium + resveratrol for each time point. (D) ALP staining of
hMSCs at day 21 cultured in osteogenic medium + resveratrol, scale bar is 100 μm. (E) qRT-PCR
showed the highest level of BGLAP in hMSCs in osteogenic medium + resveratrol for days 14
and 21. (F) OCN staining of day 21 hMSCs cultured in osteogenic medium + resveratrol, scale bar
is 50 μm. * denotes significantly higher as compared to groups denoted by **. ** denotes
significantly higher as compared to groups denoted by ***.
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5.9: Statistical Analysis
Three samples (n=3) were analyzed per condition unless otherwise stated. Studies
investigating the dose dependent effect of resveratrol on M1 macrophages and the effect
of resveratrol on hMSCs were done in duplicate trials. Error bars in graphs represent
mean ± standard deviation (SD). Two-way analysis of variance (two-way ANOVA) was
calculated using GraphPad Prism software and used to determine statistical significance
between experimental groups. One-way analysis of variance (one-way ANOVA) with a
Tukey post-test was used to calculate significance between individual groups at different
time points. Statistical significance was defined as p ≤ 0.05.
5.10: Conclusions
This

study

determined

the

effectiveness

of

resveratrol

as

a

potent

immunomodulator and promoter of osteogenesis. We set out to determine the dose
dependent effect of resveratrol on M1 macrophage phenotype as well as the regulation of
hMSC differentiation towards bone lineage.
Our experiments investigating the dose dependent regulation of inflammatory
cytokines by resveratrol indicated that M1 macrophages produce less IL-6 and TNF-α
when cultured with the anti-inflammatory polyphenol. This is coupled with higher
expression of anti-inflammatory markers VEGF, IL-10, and MRC-1 after 48 hours of
exposure to resveratrol. Cells cultured with 25 μM resveratrol demonstrated the greatest
expression of wound healing markers VEGF, MRC-1 and IL-10. Consistently, M1
macrophages cultured with 25 μM resveratrol exhibited the lowest amount of
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inflammatory cytokine TNF-α. Inflammatory marker IL-6 reduction by resveratrol was
not statistically different between the 10 μM and 25 μM groups.
To analyze osteogenic differentiation of hMSCs, we cultured cells in basal
medium, basal medium with 12.5 μM resveratrol, osteogenic medium, and osteogenic
medium with 12.5 μM resveratrol. Cells exposed to osteogenic medium supplemented
with resveratrol produced significantly higher levels of calcium, alkaline phosphatase,
and osteocalcin. These results altogether show the exciting potential for resveratrol to be
used in tissue engineering approaches for attenuating host inflammation and stimulating
osteogenic differentiation, and can be applied to a 3D scaffold design to incorporate
resveratrol.
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CHAPTER 6: ENGINEERED RESVERATROL NANOPARTICLEINCORPORATED SCAFFOLDS TO DIRECT OSTEOGENIC DIFFERENTIATION
OF HMSCS AND MODULATE INFLAMMATION OF M1 MACROPHAGES
6.1: Introduction
Biomaterial design is an essential component of successful bone tissue
engineering strategies. The ideal scaffold should be osteoinductive, osteoconductive, and
osteogenic. Osteoinductivity refers to the ability of a biomaterial to stimulate
undifferentiated stem cells to develop into bone-forming cell lineage [312].
Osteoconductive scaffolds foster bone growth on the material surface by promoting cell
attachment, proliferation, and allowing cell infiltration and matrix deposition [312, 313].
Osteogenicity signifies the scaffold contains cells that are able to differentiate into
osteoblasts [314].
PLGA microsphere-sintered scaffolds are osteoconductive, and when combined
with the appropriate cell source and signaling cues, become osteogenic as well as
osteoinductive. However, a significant challenge to bone tissue engineering strategies is
biomaterial rejection due to the host immune response, as well as scaffold integration
with the native tissue. In the previous chapter, we determined the ability of the natural
compound resveratrol to synergistically modulate inflammation and stimulate
osteogenesis of hMSCs in 2D.
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The main objective of this study is to delineate the potential of resveratrol to
accelerate the formation of bone and vasculature in tissue engineered scaffolds. The
major hypothesis underlying our effort is that resveratrol can be used to simultaneously
(1) induce the osteogenic differentiation of hMSCs seeded onto 3D porous scaffolds, and
(2) switch the invading macrophages from a pro-inflammatory M1 to a pro-angiogenic
M2 phenotype. We tested this hypothesis by assessing the time-dependent effect of a
controlled release of resveratrol on macrophage gene expression as well as hMSCs
osteogenic differentiation in 3D culture systems. Insufficient vascularization and lack of
control on host inflammatory response to implantable scaffolds are profound barriers in
regenerative medicine. The system developed in this study has the potential to be applied
to bioengineering of other musculoskeletal tissues in addition to bone.

6.2: Fabrication of PLGA Resveratrol Nanoparticles and Determination of Resveratrol
Release Profile
Nanoparticles with diameters of 150-350 nm were synthesized. Two different
molecular weights of poly(lactic-co-glycolic acid) (PLGA) (Lactel Absorbable Polymers)
were used to fabricate the resveratrol nanoparticles in order to test individual release
profiles and optimize the resveratrol dosage in the 3D scaffolds (Table 6.1). A steric
solution of 2.5% poly(vinyl alcohol) (Sigma) and 0.95 g of 2-morpholinoethanesulfonic
acid monohydrate buffer (MES) (Sigma) pH of 5.0 in 100 mL of deionized water was
created. The polymer-resveratrol conjugation solution was made by dissolving 100 mg of
PLGA and 2.5 mg of resveratrol (Sigma) in 5 mL of acetone (Macron). The polymer-
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resveratrol solution was added drop-wise at a rate of 1 mL/minute to the steric solution
while being stirred at 300 rpm. This colloidal suspension was stirred for 24 hours to
ensure complete evaporation of acetone. Nanoparticles were harvested through a
centrifugation step followed by lyophilization.
Transmission Electron Microscopy (TEM) was used to analyze nanoparticle size. Briefly,
nanoparticles were suspended in DI water and a drop of the solution was placed on a thin
carbon film. The film was placed in a vacuum to allow for water evaporation and the
sample was placed on a TEM grid. Images were taken using a JEOL 200CX transmission
electron microscope.
Using a UV-Vis Spectrophotometer, a calibration curve was generated to
correlate the absorption at 327 nm (peak absorbance of resveratrol) for various
concentrations. Nanoparticles with different molecular weights were incubated in PBS at
37°C, and the supernatant was collected every 24 hours to read the absorbance with the
UV-Vis Spectrophotometer. As it will be shown in the results, the 75:25 PLGA
demonstrated the optimum release profile and was selected for use in the remainder of
experiments.
6.3: Synthesis of PLGA Microsphere-sintered and Resveratrol Nanoparticle-incorporated
Scaffolds
Scaffolds with diameters of 10 mm and heights of 2 mm were fabricated
according to established laboratory procedures [315-317]. Briefly, PLGA (85:15 lactide
to glycolide ratio) (Lactel Absorbable Polymers) was dissolved in dichloromethane
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Table 6.1. The chemical characteristics of PLGA used to design nanoparticles for
resveratrol encapsulation and release in scaffolds.

Lactide to Glycolide Ratio
75:25
50:50

Molecular Weight (kDa)
75-100
16-29
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Functional Group
Ester Terminated
Ester Terminated

(Sigma) to form a 1:4 w/v polymer solution. The solution was slowly poured into a 1%
poly(vinyl alcohol) solution (Sigma) while being stirred at 330 rpm for 24 hours to allow
for adequate evaporation of the solvent. Vacuum filtration was used to collect the
microspheres, and the samples were washed with DI water and stored at -20°C for 24
hours. The microspheres were lyophilized to completely remove all moisture. Micron
sieves were used to isolate microspheres of diameter 500-700 μm. Microspheres of the
size range 500-700 μm were placed into stainless steel molds, heated at 80ºC for 4 hours,
and sintered into cylindrical disks. Scaffolds that were to be incorporated with
nanoparticles were sintered for 3.5 hours to account for the additional sintering time
needed to attach nanoparticles to the microspheres.
The target resveratrol release from the nanoparticles is based on 2D studies
demonstrating the optimum resveratrol dose for hMSC differentiation [310, 318], and the
desire to i) use acute inflammation to drive early osteogenesis and ii) switch macrophage
phenotype to M2 after one week to promote wound healing and angiogenesis. To this
end, initial resveratrol release is designed to attain 1-3 μM resveratrol for days 1-7, and 512.5 μM for days 7-21 to optimize inflammation modulation and osteogenesis of hMSCs.
To accomplish this, nanoparticles were suspended in DI water at a desired concentration
of 180 μg resveratrol nanoparticles/μL based on the ratio of resveratrol to PLGA in the
loaded nanoparticles (1:80). Next, 10 μL of the nanoparticle solution was placed on each
scaffold and allowed to disperse throughout the substrate. Scaffolds with nanoparticles
were sintered for an additional 30 minutes at 85ºC.
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Nanoparticle incorporation onto the PLGA scaffolds was determined using
Scanning Electron Microscopy (SEM). Briefly, scaffolds were dehydrated using an
ethanol sequence (10, 30, 50, 70, 90, 95, 95, 100, 100%) for 15 minutes each. Scaffolds
were dried overnight in a fume hood to allow for ethanol evaporation, and coated with
gold/palladium. Scaffolds were observed under Zeiss Ultra Plus FESEM after coating.

6.4: hMSC and Macrophage Seeding on Resveratrol-incorporated PLGA Scaffolds

To confirm the effect of resveratrol on osteogenic differentiation, we analyzed the
growth and lineage specification of hMSCs as cultured on resveratrol-incorporated 3D
PLGA scaffolds. PLGA scaffolds were first sterilized by immersion in 70% ethanol for
10 minutes. Scaffolds were washed 3x with PBS, and exposed to UV light for 1 hour per
side to further sterilize the substrates. To seed cells on scaffolds, hMSCs were
trypsinized, counted, centrifuged, and resuspended in basal medium at a concentration of
2,500 cells/μL. Cell suspension was added to each scaffold at the amount of 20
µL/scaffold. Samples were incubated for 20 minutes to ensure optimum cell attachment.
Next, the remaining culture medium was placed in each well containing scaffolds.
Culture medium was changed to osteogenic medium after 24 hour of incubation with
basal media. Cell proliferation was assessed using MTS colorimetric assay. Osteogenic
differentiation was analyzed based on the quantification of ALP and calcium expression.
THP-1 monocytes were differentiated to M1 macrophages at a seeding density of
50,000 cells/well of a 24 well plate. This was accomplished according to the protocol
mentioned in the Chapter 5 Section 4. Resveratrol nanoparticle-incorporated scaffolds
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were prepared using the method described in the Chapter 6 Section 3. Scaffolds were
sterilized by immersion in 70% ethanol for 10 minutes followed by rinsing 3x with PBS.
Scaffolds were placed under UV light for 1 hour per side. Scaffolds were placed in the
wells with M1 macrophages and timepoints were taken at days 3, 7, 14, and 21. Gene
expression of IL-6, TNF-α, IL-10, and VEGF was determined using qRT-PCR methods
previously described in Chapter 5 Section 4.

6.5: Statistical Analysis
Three samples (n=3) were analyzed per condition unless otherwise stated. Studies
investigating the osteogenic differentiation of hMSCs on resveratrol nanoparticleincorporated PLGA was done in duplicate trials. Error bars in graphs represent mean ±
standard deviation (SD). Two-way analysis of variance (two-way ANOVA) was
calculated using GraphPad Prism software and used to determine statistical significance
between experimental groups. One-way analysis of variance (one-way ANOVA) with a
Tukey post-test was used to calculate significance between individual groups at different
time points. Statistical significance was defined as p ≤ 0.05.

6.6: Results
Resveratrol release from the nanoparticles and incorporation into PLGA scaffolds
was assessed. Figure 6.1 includes the characterizations of PLGA scaffold with resveratrol
encapsulated nanoparticle. We observed that scaffolds possessed an interconnected
porous structure consisting of microspheres sintered together. We confirmed the
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distribution of resveratrol nanoparticles throughout the scaffolds using SEM (Figure
6.1A) and TEM (Figure 6.1B). The images demonstrated a homogenous spreading of
nanoparticles (average diameter size of 250 nm) on the surface of microspheres. As
expected, the nanoparticles were sintered into the PLGA scaffolds following the heating
step, as manifested in high magnification images. To tune the release of resveratrol
throughout the scaffolds, we varied the molecular weight of PLGA nanoparticles. Our
goal was to design a sustained release of resveratrol over several days to give enough
time for hMSC osteogenic differentiation and stimulate M1 to M2 differentiation. Figure
6.1D demonstrates the release profile of resveratrol from nanoparticles embedded in
scaffolds. As expected, the higher molecular weight of 75-100 kDa allowed for a
prolonged controlled release of resveratrol within 3D PLGA sintered microsphere
scaffolds.
Resveratrol nanoparticle-incorporated scaffolds control macrophage polarization
and enhance osteogenic differentiation of hMSCs. M1 macrophages were cultured on
resveratrol incorporated PLGA scaffolds for 21 days, and inflammatory gene expression
was analyzed at different time points (Figure 6.2). We observed the expression of IL-6
expression to sustain in day 3 to day 7 time points, and significantly drop by day 14
(Figure 6.2A). Consistently, the gene expression of inflammatory marker TNF-α was
significantly lower on later time points (Figure 6.2B). On the other hand, IL-10 and
VEGF expression were upregulated at day 7 and 14 time points (Figure 6.2C-D). These
results were consistent with our 2D experiments in that resveratrol downregulates the
inflammatory markers while stimulating the expression of angiogenic genes. A difference
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Figure 6.1 (A) SEM image of a resveratrol nanoparticle-incorporated scaffold showing the
nanoparticles on the surface of the sintered microsphere scaffolds PLGA. (B) SEM image
of a blank PLGA scaffold (control) demonstrating a smooth surface without nanoparticles.
(C) TEM image of individual resveratrol encapsulated nanoparticles. The approximate
diameter of nanoparticles was 250 nm. (D) Resveratrol release profile from the scaffolds
demonstrated a slower and more linear release when conjugated with a higher molecular
weight of PLGA.
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however is manifested in the amounts of these genes due to the 3D nature of scaffolds
and the release profile of resveratrol on scaffolds versus 2D condition.
Figure 6.3 demonstrates the results of hMSCs cultured on tissue culture
polystyrene (TCPS), 3D PLGA scaffolds, and 3D resveratrol nanoparticle-incorporated
PLGA scaffolds. We observed that the cells grow in all conditions; however, hMSCs
cultured on TCPS medium had significantly higher cell numbers than both the PLGA and
PLGA with resveratrol groups (Figure 6.3A). Furthermore, the cells cultured on blank
PLGA reached a significantly higher number compared to hMSCs grown on PLGA with
resveratrol nanoparticles.
hMSCs cultured on resveratrol incorporated scaffolds demonstrated significantly
greater of ALP expression compared to all other experimental groups at days 3, 7, 14, and
21, while hMSCs on PLGA scaffolds produced the second highest amount of ALP at
each time point as compared to TCPS (Figure 6.3B). Consistently, hMSCs cultured on
resveratrol nanoparticle scaffolds expressed a significantly higher amount of calcium at
days 14 and 21. hMSCs on blank PLGA scaffolds produce the second highest amount of
calcium a compared to the control TCPS (Figure 6.3C). These results were consistent
with the 2D experiments demonstrating the potential of resveratrol to promote osteogenic
differentiation of stem cells.
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Figure 6.2 Gene expression analysis of M1 macrophages on the resveratrol
incorporated scaffolds demonstrated (A) IL-6 expression at days 3 to 7, 14 and 21
post-culture. (B) TNF-α expression at days 3 to 7, 14 and 21 post-culture. A single
asterisk denotes a significantly higher expression of TNF-α at day 3 compared to
the previous time point. (C) IL-10 expression at days 3 to 7, 14 and 21 postculture. (D) VEGF expression at days 3 to 7, 14 and 21 post-culture. A single
asterisk denotes a significantly higher expression of VEGF at day 21. * denotes
significantly higher as compared to groups denoted by **. ** denotes significantly
higher as compared to groups denoted by ***. Results demonstrated the highest
level M2 signatory genes in the presence of resveratrol demonstrating the potential
to drive the pro-angiogenic anti-inflammatory response.
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Figure 6.3 (A) hMSC proliferation on scaffolds showed a normal cell growth
curve. (B) ALP expression by hMSCs on TCPS, PLGA scaffolds and PLGA
scaffolds with resveratrol nanoparticles. (C) ALP expression by hMSCs on
TCPS, PLGA scaffolds and PLGA scaffolds with resveratrol nanoparticles. *
denotes significantly higher as compared to groups denoted by **. ** denotes
significantly higher as compared to groups denoted by ***.
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6.7: Discussion
Our study addresses fundamental issues facing osseointegration of biomaterial
grafts

in

an

inflammatory microenvironment.

We set out

to engineer an

immunomodulatory and osteoinductive scaffold that can harness the osteogenic and
wound healing potential of immune cells, as well as program hMSCs towards bone tissue
formation. To accomplish this goal, we demonstrated the ability of resveratrol to control
macrophage phenotype from inflammatory to wound healing as well as stimulate
osteogenic differentiation of hMSCs. Building on these 2D and 3D proof-of-concept
experiments, we designed a specific resveratrol nanoparticle release profile within PLGA
scaffolds that would i) control macrophage phenotype and subsequent cytokine secretion
and ii) drive the osteogenic differentiation of hMSCs. This resveratrol nanoparticle
incorporated scaffold is a novel approach to enhance graft integration and assimilation
with native tissue.
Researchers have explored many options to modulate the immune response to
prevent biomaterial rejection, such as using polymeric coatings, steroidal antiinflammatory drugs, and angiogenic factors. These methods have faced many limitations
due to immunogenicity, decomposition during the manufacturing process, and poor
adhesion characteristics. Anti-inflammation pharmaceutical drugs only temporary
suppress inflammation and have been known to reduce angiogenic factors which in turn
delays wound healing. Finally, despite their important role in inflammatory cascade of
events, the use of angiogenic growth factors is only partially effective due to its
physiologic side effects.
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Instead of trying to counteract inflammation, our approach aims to utilize a
natural polyphenol to regulate immune cell behavior and use their expressed signaling
molecules to drive the osteogenic differentiation of hMSCs. Our methods build on the
central concepts of the anti-inflammatory and osteogenic properties of resveratrol as well
as the known angiogenic signaling molecules produced by macrophages. To this end, we
fabricated resveratrol nanoparticle-incorporated scaffolds with a controlled release profile
that have the potential to revolutionize biomaterial assimilation with native bone tissue.
Our 2D proof of concept experiments described in Chapter 5 signify that M1
macrophages secrete less IL-6 and TNF-α when exposed to resveratrol. Furthermore, we
found that M1 macrophages produce higher levels of anti-inflammatory markers VEGF,
IL-10, and MRC-1 after 48 hours of culture with the anti-inflammatory polyphenol. From
our results, we determined that 25 μM resveratrol tempers inflammation to the greatest
extent as compared to the other concentrations. However, the optimized time scale and
amount of resveratrol released from the nanoparticles should account for the target
temporal concentration for both osteogenesis and macrophage phenotype polarization.
The use of resveratrol as a stimulator of osteogenesis has been previously
demonstrated for hMSCs, human adipose derived stem cells (hADSCs), and preosteoblastic MC3T3-E1 cells [308-311, 318-323]. Furthermore, studies have shown
resveratrol to affect proliferation and osteogenesis in a dose-dependent manner. hADSCs
cultured with 12.5 μM, 25 μM, and 50 μM resveratrol showed the highest proliferation
rate when exposed to 12.5 μM resveratrol, and the highest levels of ALP when cultured
with 25 μM resveratrol. Doses of 50 μM resulted in extremely low cell numbers and ALP
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production. ADSCs cultured with resveratrol exhibited the highest levels of osteocalcin
and osteoprotegerin at a concentration of 12.5 μM [318]. Another study concluded that
doses of 25 μM resveratrol are potentially cytotoxic, and that 12.5 μM resveratrol results
in the greatest mineralized matrix after 4 weeks in vivo [310]. Additionally, hMSCs
cultured with varying doses of resveratrol produced the highest calcium deposition and
greatest proliferative capabilities when exposed to a concentration of 10 μM [323]. Based
on these studies, and the fact that M1 macrophages switch phenotype to M2 when
exposed to doses as low as 1 μM resveratrol, we selected a target resveratrol
concentration of 12.5 μM to stimulate osteogenesis of hMSCs in 2D. Consistent with
these, we observed the greatest calcium deposition and ALP expression from cells
cultured in osteogenic medium + 12.5 μM. Furthermore, OCN levels were the highest for
hMSCs cultured in osteogenic medium + 12.5 μM. To optimize macrophage control and
osteogenic differentiation of hMSCs, we targeted a nanoparticle release profile of
approximately 1-3 μM resveratrol per day for days 1-7, then approximately 5-12.5 μM
resveratrol per day for days 7-21.
To design a biomaterial that allows for modulation of immune response, one must
first determine how specific aspects of inflammation, such as macrophage phenotype,
influence wound healing and osteogenesis. Preliminary investigations on total joint
replacement materials and the surrounding tissue histology from either i) joints that had
become loose due to osteolysis, and ii) joints implanted in osteoarthritic patients, have
found that the former tissue produced many pro-inflammatory M1 macrophages while the
latter demonstrated wound healing M2 macrophages [324, 325]. In another recent study,
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porosity was found to drive a higher ratio of M2/M1 macrophages when compared to the
non-porous control [326]. Furthermore, scaffolds composed of natural ECM can switch
macrophage phenotype to predominantly wound healing by 7-14 days after implantation
[327-329]. The common thread that relates all these findings is that they all rely on
altering the cytokine release profile by monocyte and macrophages to attenuate the
inflammatory response to the biomaterial [330, 331].
Although chronic inflammation is detrimental to wound healing and assimilation
of graft with native tissue, recent studies have demonstrated the benefits of monocytes
and macrophages in stimulating osteogenic differentiation of stem cells. In a recent
published work, hMSCs were cultured in conditioned medium (CM) from M1
macrophages, M2 macrophages, and monocytes, and analyzed for hallmark osteogenic
markers such as RUNX2, ALP, and bone morphogenetic protein-2 (BMP-2). hMSCs
cultured with M1 CM expressed the highest levels of RUNX2, ALP, and BMP-2 [332].
Another study demonstrated that a member of the IL-6 pro-inflammatory cytokine
family, Oncostatin M (OSM), produced by M1 macrophages promoted osteogenic
differentiation of hMSCs and inhibited adipogenesis [333]. Macrophages secrete several
osteogenic signaling molecules such as bone morphogenic protein-2 (BMP-2), 1, 25dihydroxyvitamin D3, interleukin-1 beta (IL-1β), and IL-6 [334-336]. During fracture
healing, cytokine members of the TGF- β superfamily, such as BMP, promote different
stages of wound repair. BMP-2 peaks in expression levels early in the healing process,
mediates a cascade of other BMPs associated with intramembranous and endochondral
ossification [337]. TNF-α is another cytokine secreted by macrophages during the initial
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inflammatory response that is responsible for recruiting hMSCs, and promoting cell
survival [338]. Additionally, macrophages secrete angiogenic growth factors such as
VEGF and PDGF, and these cytokines are important mediators in bone remodeling.
Specifically, the VEGF family recruits endothelial cells, osteoblasts, and osteoclasts, and
can promote microvascular endothelial cells to secrete BMPs in a hypoxic
microenvironment found in fractured bone tissue [339-341].
In our proof of concept 3D experiments, we were able to successfully engineer a
scaffold with a specific resveratrol release profile. M1 macrophages and hMSCs were
individually placed on the scaffolds and cultured for 21 days. The gene expression profile
of the macrophages showed moderately high expression of IL-6 for day 3 and day 7, and
was significantly reduced by day 14. VEGF expression levels were relatively low until
day 14, but significantly increased by day 21. This in itself overcomes a critical factor in
tissue engineering approaches since lack of vascularization generally leads to failure of
the graft. Our method of inducing endogenous VEGF secretion from native macrophages
keeps levels physiologically relevant, therefore the risk of overexposing surrounding
tissue to high levels of this angiogenic growth factor is almost nonexistent.
Stem cells cultured on the resveratrol-incorporated scaffolds expressed the highest
levels of calcium and ALP, demonstrating the effectiveness of the controlled resveratrol
release. The mechanism by which resveratrol induces osteogenesis is under deep
investigation. Preliminary work by scientists has shown resveratrol to trigger Wnt
signaling pathway leading to the upregulation of RUNX2 expression, the transcription
factor essential for cell differentiation into osteoblasts [308, 342]. Resveratrol also
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promotes osteogenesis through SIRT-1, and it has been shown that FOXO3A protein
expression and SIRT-1 activation operate synergistically to mediate RUNX2 gene
transcription [309, 322]. When embryonic stem cell-derived mesenchymal progenitors
are cultured in adipogenic medium containing resveratrol, RUNX2 and OCN are
upregulated while adipogenic genes PPARγ2 and LEPTIN are suppressed [322]. This is
extremely important because PPARγ2 can prevent RUNX2 transcription and inhibit
osteogenesis [343, 344]. Further studies are warranted to illucidate the temporal effect of
resveratrol of osteogenic signaling pathways using appropriate in vitro and in vivo
models.

6.8: Conclustions
For the first time, we demonstrated a novel approach based on the use of
resveratrol to concurrently modulate inflammation, stimulate angiogenic growth factor
release, and promote osteogenesis. Our results demonstrated the polarization of M1
macrophages from pro-inflammatory to wound healing M2 macrophages releasing proangiogenic growth factor VEGF.

Resveratrol also accelerated the osteogenic

differentiation of hMSCs in both 2D and 3D tissue engineering culture systems.
Strikingly, the temporal release profile and amount of resveratrol can be tuned at the
same time to concurrently promote osteogenesis and M2 polarization. Together, this
study introduces a ground breaking synergistic method to overcome prolonged
inflammation in response to implanted biomaterials in bone tissue engineering strategies,
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and to harness the inflammatory response towards effective osseointegration and graft
success.
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CHAPTER 7: SUMMARY OF FINDINGS
The results of the research presented in this dissertation show methods of
directing stem cell differentiation towards bone tissue using 3D engineered substrates.
Additionally, these findings demonstrate a novel approach for harnessing inflammation to
accelerate wound healing and promote osseointegration of implanted scaffolds with
native host tissue. This was accomplished by three main studies.
The first investigated the use of decellularized scaffolds containing native bone
extracellular matrix to direct hESC differentiation towards osteogenic lineage.
Osteomimetic PLGA scaffolds were fabricated by utilizing a microsphere-sintering
technique, followed by seeding hOBs on the substrates for 14 days in order to deposit
bone ECM on the surface of the polymer. Analysis of the scaffold following hOB
decellularization indicated that the deposited ECM had a similar composition to that of
bone ECM found in vivo. The potential of these scaffolds as bone graft substitutes was
evaluated by the in vitro differentiation of hESCs on the osteomimetic substrates. The
decellularized scaffolds promoted cell adhesion, proliferation, and osteogenic
differentiation. Incorporating native components of bone ECM with PLGA scaffolds has
proven to be a successful approach to tissue engineering bone, however a more
meticulous study is warranted to parse the in vivo mechanisms by which ECM proteins
regulate osteogenesis.
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The next study determined the effectiveness of resveratrol as a modulator of
inflammation and promoter of osteogenesis in 2D. Our experiments investigating the
dose dependent regulation of inflammatory cytokines by resveratrol demonstrated that
M1 macrophages produce less IL-6 and TNF-α when cultured with resveratrol. This is
paired with greater expression levels of anti-inflammatory markers VEGF, IL-10, and
MRC-1 after 48 hours of exposure to the anti-inflammatory polyphenol. M1 macrophages
cultured with 25 μM resveratrol demonstrated the greatest expression of wound healing
markers VEGF, MRC-1 and IL-10. Consistently, M1 macrophages cultured with 25 μM
resveratrol exhibited the lowest amount of inflammatory cytokine TNF-α. Inflammatory
marker IL-6 reduction by resveratrol was not statistically different between the 10 μM
and 25 μM groups. After investigating the immunomodulatory effects of resveratrol, we
examined how resveratrol influences hMSC lineage commitment. To analyze osteogenic
differentiation of hMSCs, we cultured cells in basal medium, basal medium with 12.5 μM
resveratrol, osteogenic medium, and osteogenic medium with 12.5 μM resveratrol. Cells
exposed to osteogenic medium supplemented with resveratrol expressed significantly
higher levels of calcium, alkaline phosphatase, and osteocalcin as compared to the
controls. These results altogether show the exciting potential for resveratrol to be used in
tissue engineering approaches for attenuating host inflammation and stimulating
osteogenic differentiation, and can be applied to a 3D scaffold design to integrate
resveratrol.
The last study investigated the incorporation of resveratrol in 3D scaffolds, and
observed the efficacy of these scaffolds for immunomodulation and osteogenesis. For the
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first time, we demonstrated a novel approach based on the use of resveratrol to
concurrently modulate inflammation, stimulate angiogenic growth factor release, and
promote osteogenesis. Our results indicated the phenotypic switch of M1 macrophages
from pro-inflammatory to wound healing M2 macrophages on the resveratrolincorporated scaffolds. Along with secreting anti-inflammatory cytokines, the M2
macrophages released pro-angiogenic growth factor VEGF. Furthermore, resveratrol
integrated scaffolds accelerated the osteogenic differentiation of hMSCs as compared to
cells on control PLGA and TCPS. The temporal release profile and amount of resveratrol
leaving the nanoparticles can be tuned to concurrently promote osteogenesis and
macrophage polarization. This study introduces a ground breaking synergistic method to
overcome inflammation in response to implanted biomaterials in bone tissue engineering
strategies, and to harness the inflammatory response towards successful osseointegration
of the graft with host tissue.
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CHAPTER 8: FUTURE WORK
• Parse the in vivo mechanisms by which ECM proteins regulate osteogenesis
•

Determine which ECM components have the greatest effect on osteogenic
differentiation of hESCs cultured on osteomimetic PLGA

•

Implant osteomimetic scaffold in animal model to study in vivo capabilities of the
graft to repair a critical size defect in bone

•

Investigate the interplay between hMSCs and macrophages (M0, M1 and M2) in 2D

•

Determine how macrophages regulate the osteogenic differentiation of hMSCs on 3D
resveratrol-incorporated scaffolds

• Implant resveratrol PLGA scaffolds in animal model to investigate how the scaffold
modulates the in vivo inflammation response as well as promotes osteogenesis and
osseointegration
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